RNA editing compositions and methods of use
Engineered guide RNAs with specific structural features enhance the specificity and efficiency of adenosine editing in target RNAs by forming guide-target RNA scaffolds, addressing the challenges of current RNA editing technologies and improving editing precision.
Patent Information
- Application Number
- JP2024525055
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-24
- Filing Date
- 2022-10-26
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024542983000001_ABST
Abstract
Description
[Technical Field]
[0001] cross reference This application is a continuation of Provisional Application No. 63 / 271,889 filed October 26, 2021, Provisional Application No. 63 / 277,707 filed November 10, 2021, Provisional Application No. 63 / 284,737 filed December 1, 2021, Provisional Application No. 63 / 296,955 filed January 6, 2022, Provisional Application No. 63 / 30 filed January 27, 2022, and Provisional Application No. 63 / 31,965 filed January 1, 2022. This application claims priority under 35 U.S.C. § 119 from Provisional Application No. 3,659, filed February 4, 2022, Provisional Application No. 63 / 306,809, filed April 5, 2022, and Provisional Application No. 63 / 327,380, filed April 5, 2022, and Provisional Application No. 63 / 345,069, filed May 24, 2022, the disclosures of which are incorporated herein by reference in their entireties. Summary of the Invention
[0002] Disclosed herein are engineered guide RNAs or polynucleotide sequences encoding engineered guide RNAs, wherein upon hybridization of the engineered guide RNA to a sequence of a target RNA, the sequences of the engineered guide RNA and the target RNA form a guide-target RNA scaffold, the guide-target RNA scaffold comprising (i) a region comprising at least one structural feature selected from the group consisting of a bulge, a wobble base pair, an internal loop, a mismatch, a hairpin, and any combination thereof, and wherein upon contacting the guide-target RNA scaffold with an RNA editing entity, the RNA editing entity comprises a region comprising at least one structural feature selected from the group consisting of a bulge, a wobble base pair, an internal loop, a mismatch, a hairpin, and any combination thereof, within the guide-target RNA scaffold. and (ii) a first internal loop and a second internal loop adjacent to opposite ends of the guide target RNA scaffold region of (i), wherein the first internal loop is 5' of the region comprising at least one structural feature and the second internal loop is 3' of the region comprising at least one structural feature, and the first internal loop and the second internal loop facilitate an increased amount of on-target adenosine editing in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop. In some embodiments, the first internal loop and the second internal loop facilitate a decreased amount of off-target adenosine editing in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop. In some embodiments, the first internal loop is a symmetric internal loop and the second internal loop is a symmetric internal loop. In some embodiments, the first internal loop and the second internal loop are symmetric internal loops that are independently 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loops, wherein the first number is the number of nucleotides contributed to the symmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number isThe number of nucleotides contributed to the symmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop is an asymmetric internal loop and the second internal loop is an asymmetric internal loop. In some embodiments, the first inner loop and the second inner loop are independently: 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15 ,7 / 16,7 / 17,7 / 18,7 / 19,7 / 20,8 / 5,8 / 6,8 / 7,8 / 9,8 / 10,8 / 11,8 / 12,8 / 13,8 / 14,8 / 15,8 / 16,8 / 17,8 / 18,8 / 19,8 / 20,9 / 5,9 / 6,9 / 7,9 / 8,9 / 10,9 / 11,9 / 12,9 / 13,9 / 14,9 / 15,9 / 16,9 / 17,9 / 18,9 / 19,9 / 20,10 / 5,10 / 6,10 / 7,10 / 8,10 / 9,10 / 11,10 / 12,10 / 13,10 / 14,10 / 15,1 0 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 14 / 10, 14 / 11, 14 / 12, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14, 15 / 16, 15 / 17, 15 / 18, 15 / 19,15 / 20, 16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, The asymmetric internal loop is a 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop, where the first number is the number of nucleotides contributed to the asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop is a symmetric internal loop and the second internal loop is an asymmetric internal loop. In some embodiments, the first inner loop is a symmetric inner loop that is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric inner loop, and the second inner loop is a 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9,8 / 10、8 / 11、8 / 12、8 / 13、8 / 14、8 / 15、8 / 16、8 / 17、8 / 18、8 / 19、8 / 20、9 / 5、9 / 6、9 / 7、9 / 8、9 / 10、9 / 11、9 / 12、9 / 13、9 / 14、9 / 15、9 / 16、9 / 17、9 / 18、9 / 19、9 / 20、10 / 5、10 / 6、10 / 7、10 / 8、10 / 9、10 / 11、10 / 12、10 / 13、10 / 14、10 / 15、10 / 16、10 / 17、10 / 18、10 / 19、10 / 20、11 / 5、11 / 6、11 / 7、11 / 8、11 / 9、11 / 10、11 / 12、11 / 13、11 / 14、11 / 15、11 / 16、11 / 17、11 / 18、11 / 19、11 / 20、12 / 5、12 / 6、12 / 7、12 / 8、12 / 9、12 / 10、12 / 11、12 / 13、12 / 14、12 / 15、12 / 16、12 / 17、12 / 18、12 / 19、12 / 20、13 / 5、13 / 6、13 / 7、13 / 8、13 / 9、13 / 10、13 / 11、13 / 12、13 / 14、13 / 15、13 / 16、13 / 17、13 / 18、13 / 19、13 / 20、14 / 5、14 / 6、14 / 7、14 / 8、14 / 9、14 / 10、14 / 11、14 / 12、14 / 13、14 / 15、14 / 16、14 / 17、14 / 18、14 / 19、14 / 20、15 / 5、15 / 6、15 / 7、15 / 8、15 / 9、15 / 10、15 / 11、15 / 12、15 / 13、15 / 14、15 / 16、15 / 17、15 / 18、15 / 19、15 / 20、16 / 5、16 / 6、16 / 7、16 / 8、16 / 9、16 / 10、16 / 11、16 / 12、16 / 13、16 / 14、16 / 15、16 / 17、16 / 18、16 / 19、16 / 20、17 / 5、17 / 6、17 / 7、17 / 8、17 / 9、17 / 10、17 / 11、17 / 12、17 / 13、17 / 14、17 / 15、17 / 16、17 / 18、17 / 19、17 / 20、18 / 5、18 / 6、18 / 7、18 / 8、18 / 9、18 / 10、18 / 11、18 / 12、18 / 13、18 / 14、18 / 15、18 / 16、18 / 17、18 / 19、18 / 20、19 / 5、19 / 6、19 / 7、19 / 8、19 / 9、19 / 10、19 / 11、19 / 12、19 / 13、19 / 14、19 / 15、19 / 16、19 / 17、19 / 18、19 / 20、20 / 5、20 / 6、20 / 7、20 / 8、20 / 9、The asymmetric internal loop is a 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop, where the first number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold, and the second number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop is an asymmetric internal loop and the second internal loop is a symmetric internal loop. In some embodiments, the first inner loop is 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9 ,7 / 10,7 / 11,7 / 12,7 / 13,7 / 14,7 / 15,7 / 16,7 / 17,7 / 18,7 / 19,7 / 20,8 / 5,8 / 6,8 / 7,8 / 9,8 / 10,8 / 11,8 / 12,8 / 13,8 / 14,8 / 15,8 / 16,8 / 17,8 / 18,8 / 19,8 / 20,9 / 5,9 / 6,9 / 7,9 / 8,9 / 10,9 / 11,9 / 12,9 / 13,9 / 14,9 / 15,9 / 16,9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20,14 / 5、14 / 6、14 / 7、14 / 8、14 / 9、14 / 10、14 / 11、14 / 12、14 / 13、14 / 15、14 / 16、14 / 17、14 / 18、14 / 19、14 / 20、15 / 5、15 / 6、15 / 7、15 / 8、15 / 9、15 / 10、15 / 11、15 / 12、15 / 13、15 / 14、15 / 16、15 / 17、15 / 18、15 / 19、15 / 20、16 / 5、1、 6 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 1 8 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 20 / 7, 20 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 asymmetric internal loop; and the second internal loop is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loop, wherein the first number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop and the second internal loop comprise the same number of bases. In some embodiments, the first internal loop and the second internal loop comprise different numbers of bases. In some embodiments, the first internal loop comprises a greater number of bases than the second internal loop. In some embodiments, the second internal loop comprises a greater number of bases than the first internal loop. In some embodiments, the first internal loop and the second internal loop independently comprise at least about 5 bases to at least about 20 bases of the engineered guide RNA and at least about 5 bases to at least about 20 bases of the target RNA.In some embodiments, the engineered guide RNA includes a cytosine that is present in the guide-target RNA scaffold opposite the on-target adenosine edited by the RNA editing entity when the engineered guide RNA is hybridized to the target RNA, thereby forming an A / C mismatch in the guide-target RNA scaffold. In some embodiments, the first internal loop and the second internal loop are positioned the same number of bases from the A / C mismatch relative to the base of the first internal loop and the base of the second internal loop that are closest to the A / C mismatch. In some embodiments, the first internal loop is positioned at least about 5 bases away from the A / C mismatch relative to the base of the first internal loop that is closest to the A / C mismatch. In some embodiments, the first internal loop is positioned about 1 base from the A / C mismatch to about 30 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and optionally, the first internal loop is positioned 6, 10, 12, or 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned at least about 12 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch, and optionally, the second internal loop is positioned 24, 30, 33, or 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the target RNA is an mRNA selected from the group consisting of ABCA4, APP, CFTR, DMPK, DUX4, GAPDH, GBA, GRN, HEXA, LIPA, LRRK2, MAPT, PINK1, PMP22, SERPINA1, SNCA, or SOD1, a fragment of any one of these, and any combination thereof.In some embodiments, the target RNA is ABCA4, and ABCA4 comprises a target mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 1-105, 2729-2761, or 2772-2843. In some embodiments, the target RNA is APP, and a targeted mutation is introduced into the APP RNA such that the polypeptide encoded by the APP RNA after modification comprises a polypeptide mutation selected from the group consisting of K670E, K670R, K670G, M671V, A673V, A673T, D672G, E682G, H684R, K687R, K687E, K687G, I712X, T714X, and any combination thereof. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, hi some embodiments, the first internal loop is positioned 10 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch.In some embodiments, the second internal loop is positioned about 15 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 112-114. In some embodiments, the target RNA is SERPINA1, wherein SERPINA encodes a polypeptide comprising an E342K mutation. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 24 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2762-2768 or 3083-3086.In some embodiments, the target RNA is LRRK2, and LRRK2 is selected from the group consisting of E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E, Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165P, I1192V, H1 216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647T, Y1699 C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I2012T, G20 The present invention encodes a polypeptide having a polypeptide mutation selected from the group consisting of 19S, I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, Q2490NfsX3, and any combination thereof. In some embodiments, the first internal loop is positioned about 7 bases from the A / C mismatch to about 30 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 10 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases from the A / C mismatch to about 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch.In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 118-167, 2686-2728, 2769-2771, 2844-3078, or 3081-3082. In some embodiments, the target RNA is SNCA, and the SNCA comprises a target mutation for RNA editing selected from the group consisting of a translation initiation site (TIS) ATG to GTG at codon 1 and codon 5, and an AUG at position 265 of exon 2. In some embodiments, the first internal loop is positioned about 6 bases from the A / C mismatch to about 20 bases from the A / C mismatch, relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 6 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 15 bases away from the A / C mismatch to about 38 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second The internal loop is positioned 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2480-2681. In some embodiments, the target RNA is MAPT, and MAPT comprises a target mutation for RNA editing at the translation start site (TIS). In some embodiments, the first internal loop is positioned about 5 bases away from the A / C mismatch to about 15 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 15 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 115-117, 1519-2479, or 2682-2685. In some embodiments, the target RNA is DUX4. In some embodiments, the first internal loop is positioned about 1 base from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 6 bases away from the A / C mismatch relative to the base of the first internal loop that is closest to the A / C mismatch, and in some embodiments, the second internal loop is positioned about 15 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch relative to the base of the second internal loop that is closest to the A / C mismatch.In some embodiments, the second internal loop is positioned 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 172-1518. In some embodiments, the target RNA is a GRN. In some embodiments, the first internal loop is positioned about 5 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases from the A / C mismatch to about 38 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a length of at least about 60 bases. In some embodiments, the engineered guide RNA comprises a length of about 65 bases to about 150 bases. In some embodiments, the at least one structural feature comprises a bulge. In some embodiments, the bulge comprises an asymmetric bulge. In some embodiments, the bulge comprises a symmetric bulge. In some embodiments, the bulge comprises, independently, about 1 base to about 4 bases of the engineered guide RNA and about 0 bases to about 4 bases of the target RNA. In some embodiments, the at least one structural feature comprises an internal loop. In some embodiments, the internal loop comprises an asymmetric internal loop. In some embodiments, the internal loop comprises a symmetric internal loop. In some embodiments, the internal loop comprises, independently, about 5 to about 10 bases of either the engineered guide RNA or the target RNA. In some embodiments, at least one structural feature comprises a hairpin.In some embodiments, the hairpin comprises a length of about 3 bases to about 15 bases long. In some embodiments, the RNA editing entity is endogenous to a mammalian cell. In some embodiments, the RNA editing entity is an adenosine deaminase acting on RNA (ADAR) enzyme, a catalytically active fragment thereof, or a fusion polypeptide thereof. In some embodiments, the RNA editing entity is an ADAR enzyme. In some embodiments, the ADAR enzyme comprises human ADAR (hADAR). In some embodiments, the ADAR enzyme comprises ADAR1 or ADAR2. In some embodiments, the target RNA is mRNA or pre-mRNA. In some embodiments, the engineered guide RNA further comprises at least one chemical modification. In some embodiments, the at least one chemical modification comprises a 2'-O-methyl group on the ribose sugar of a nucleotide of the engineered guide RNA. In some embodiments, the at least one chemical modification comprises a phosphothioate modification of the backbone of the engineered guide RNA. In some embodiments, the engineered guide comprises a total polynucleotide length of at least about 65 bases. In some embodiments, the engineered guide comprises a total polynucleotide length range of about 65 bases to about 100 bases. In some embodiments, the engineered guide RNA is a circular guide RNA.
[0003] Also disclosed herein are engineered guide RNAs or polynucleotide sequences encoding engineered guide RNAs, wherein upon hybridization, the sequences of the engineered guide RNA and the target RNA form a guide-target RNA scaffold, the guide-target RNA scaffold comprising: (i) a microfootprint comprising at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a wobble base pair, a hairpin, and any combination thereof, such that upon contacting the guide-target RNA scaffold with an RNA editing entity, the RNA editing entity edits an on-target adenosine in a target RNA within the guide-target RNA scaffold; and (ii) a barbell macrofootprint comprising a first internal loop that is 5' of the microfootprint and a second internal loop that is 3' of the microfootprint, wherein the barbell macrofootprint facilitates increased amounts of editing of the on-target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the barbell macrofootprint. In some embodiments, the first internal loop and the second internal loop facilitate a reduced amount of off-target adenosine editing in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop. In some embodiments, the first internal loop is a symmetric internal loop and the second internal loop is a symmetric internal loop. In some embodiments, the first internal loop and the second internal loop are independently symmetric internal loops that are independently 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loops, wherein the first number is the number of nucleotides contributed to the symmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the symmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first inner loop is an asymmetric inner loop and the second inner loop is an asymmetric inner loop.The first inner loop and the second inner loop are independently: 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 1 2, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 14 / 10 , 14 / 11, 14 / 12, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14, 15 / 16, 15 / 17, 15 / 18, 15 / 19, 15 / 20, 16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9,17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 2 The asymmetric internal loop is a 0, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop, where the first number is the number of nucleotides contributed to the asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop is a symmetric internal loop and the second internal loop is an asymmetric internal loop. In some embodiments, the first inner loop is a symmetric inner loop that is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric inner loop, and the second inner loop is a symmetric inner loop that is a 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12 , 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18,9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 1 4 / 8, 14 / 9, 14 / 10, 14 / 11, 14 / 12, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14 ,15 / 16,15 / 17,15 / 18,15 / 19,15 / 20,16 / 5,16 / 6,16 / 7,16 / 8,16 / 9,16 / 10,16 / 11,16 / 12,16 / 13,16 / 14,16 / 15,16 / 17,16 / 18,16 / 19,16 / 20,17 / 5,1 7 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 1 8 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 is an asymmetric inner loop, and the first number isthe first number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold, and the second number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop is an asymmetric internal loop and the second internal loop is a symmetric internal loop. In some embodiments, the first inner loop is 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20 ... 4, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 1 1, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 1 2 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 14 / 10, 14 / 11, 14 / 12, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6,15 / 7、15 / 8、15 / 9、15 / 10、15 / 11、15 / 12、15 / 13、15 / 14、15 / 16、15 / 17、15 / 18、15 / 19、15 / 20、16 / 5、16 / 6、16 / 7、16 / 8、16 / 9、16 / 10、16 / 11、16 / 12、16 / 13、16 / 14、16 / 15、16 / 17、1、 6 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13 , 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop, and the second internal loop is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loop, wherein the first number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold, and the second number is the number of nucleotides contributed to the symmetric or asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. In some embodiments, the first internal loop and the second internal loop comprise the same number of bases. In some embodiments, the first internal loop and the second internal loop comprise different numbers of bases. In some embodiments, the first internal loop comprises a greater number of bases than the second internal loop. In some embodiments, the second internal loop comprises a greater number of bases than the first internal loop. In some embodiments, the first internal loop and the second internal loop independently comprise at least about 5 bases to at least about 20 bases of the engineered guide RNA and at least about 5 bases to at least about 20 bases of the target RNA.In some embodiments, the engineered guide RNA includes a cytosine that is present in the guide-target RNA scaffold opposite the on-target adenosine edited by the RNA editing entity when the engineered guide RNA is hybridized to the target RNA, thereby forming an A / C mismatch in the guide-target RNA scaffold. In some embodiments, the first internal loop and the second internal loop are positioned the same number of bases from the A / C mismatch relative to the base of the first internal loop and the base of the second internal loop that are closest to the A / C mismatch. In some embodiments, the first internal loop is positioned at least about 5 bases away from the A / C mismatch relative to the base of the first internal loop that is closest to the A / C mismatch. In some embodiments, the first internal loop is positioned about 1 base from the A / C mismatch to about 30 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and optionally, the first internal loop is positioned 6, 10, 12, or 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned at least about 12 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch, and optionally, the second internal loop is positioned 24, 30, 33, or 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the target RNA is an mRNA selected from the group consisting of ABCA4, APP, CFTR, DMPK, DUX4, GAPDH, GBA, GRN, HEXA, LIPA, LRRK2, MAPT, PINK1, PMP22, SERPINA1, SNCA, or SOD1, a fragment of any one of these, and any combination thereof.In some embodiments, the target RNA is ABCA4, and ABCA4 comprises a target mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 1-105, 2729-2761, or 2772-2843. In some embodiments, the target RNA is APP, and a targeted mutation is introduced into the APP RNA such that the polypeptide encoded by the APP RNA after modification comprises a polypeptide mutation selected from the group consisting of K670E, K670R, K670G, M671V, A673V, A673T, D672G, E682G, H684R, K687R, K687E, K687G, I712X, T714X, and any combination thereof. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, hi some embodiments, the first internal loop is positioned 10 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch.In some embodiments, the second internal loop is positioned about 15 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 112-114. In some embodiments, the target RNA is SERPINA1, wherein SERPINA encodes a polypeptide comprising an E342K mutation. In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 24 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2762-2768 or 3083-3086.In some embodiments, the target RNA is LRRK2, and LRRK2 is selected from the group consisting of E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E, Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165P, I1192V, H1 216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647T, Y1699 C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I2012T, G20 The present invention encodes a polypeptide having a polypeptide mutation selected from the group consisting of 19S, I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, Q2490NfsX3, and any combination thereof. In some embodiments, the first internal loop is positioned about 7 bases from the A / C mismatch to about 30 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 10 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases from the A / C mismatch to about 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch.In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 118-167, 2686-2728, 2769-2771, 2844-3078, or 3081-3082. In some embodiments, the target RNA is SNCA, and the SNCA comprises a target mutation for RNA editing selected from the group consisting of a translation initiation site (TIS) ATG to GTG at codon 1 and codon 5, and an AUG at position 265 of exon 2. In some embodiments, the first internal loop is positioned about 6 bases from the A / C mismatch to about 20 bases from the A / C mismatch, relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 6 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 15 bases away from the A / C mismatch to about 38 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2480-2681. In some embodiments, the target RNA is MAPT, and MAPT comprises a targeted mutation for RNA editing at the translation start site (TIS). In some embodiments, the first internal loop is positioned about 5 bases from the A / C mismatch to about 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 115-117, 1519-2479, or 2682-2685. In some embodiments, the target RNA is DUX4. In some embodiments, the first internal loop is positioned about 1 base away from the A / C mismatch to about 20 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 6 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 15 bases from the A / C mismatch to about 40 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch.In some embodiments, the second internal loop is positioned 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 172-1518. In some embodiments, the target RNA is a GRN. In some embodiments, the first internal loop is positioned about 5 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases from the A / C mismatch to about 38 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the engineered guide RNA comprises a length of at least about 60 bases. In some embodiments, the engineered guide RNA comprises a length of about 65 bases to about 150 bases. In some embodiments, the at least one structural feature comprises a bulge. In some embodiments, the bulge comprises an asymmetric bulge. In some embodiments, the bulge comprises a symmetric bulge. In some embodiments, the bulge comprises, independently, about 1 base to about 4 bases of the engineered guide RNA and about 0 bases to about 4 bases of the target RNA. In some embodiments, the at least one structural feature comprises an internal loop. In some embodiments, the internal loop comprises an asymmetric internal loop. In some embodiments, the internal loop comprises a symmetric internal loop. In some embodiments, the internal loop comprises, independently, about 5 to about 10 bases of either the engineered guide RNA or the target RNA. In some embodiments, at least one structural feature comprises a hairpin.In some embodiments, the hairpin comprises a length of about 3 bases to about 15 bases long. In some embodiments, the RNA editing entity is endogenous to a mammalian cell. In some embodiments, the RNA editing entity is an adenosine deaminase acting on RNA (ADAR) enzyme, a catalytically active fragment thereof, or a fusion polypeptide thereof. In some embodiments, the RNA editing entity is an ADAR enzyme. In some embodiments, the ADAR enzyme comprises human ADAR (hADAR). In some embodiments, the ADAR enzyme comprises ADAR1 or ADAR2. In some embodiments, the target RNA is mRNA or pre-mRNA. In some embodiments, the engineered guide RNA further comprises at least one chemical modification. In some embodiments, the at least one chemical modification comprises a 2'-O-methyl group on the ribose sugar of a nucleotide of the engineered guide RNA. In some embodiments, the at least one chemical modification comprises a phosphothioate modification of the backbone of the engineered guide RNA. In some embodiments, the engineered guide comprises a total polynucleotide length of at least about 65 bases. In some embodiments, the engineered guide comprises a total polynucleotide length range of about 65 bases to about 100 bases. In some embodiments, the engineered guide RNA is a circular guide RNA.
[0004] Also disclosed herein are polynucleotides that encode the engineered guide RNAs described herein.
[0005] Also disclosed herein are delivery vehicles comprising the engineered guide RNAs described herein or the polynucleotides described herein. In some embodiments, the delivery vehicle is selected from the group consisting of a delivery vector, a liposome, a particle, and any combination thereof. In some embodiments, the delivery vehicle is a delivery vector, and the delivery vector comprises a viral vector. In some embodiments, the viral vector comprises an adeno-associated viral (AAV) vector or a derivative thereof. In some embodiments, the AAV vector or derivative thereof is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV.rh8, AAV.rh10, AAV.rh20, AAV.rh39, AAV.Rh74, AAV.RHM4-1, AAV.hu37, AAV.Anc80, AAV.Anc80L65, AAV.7m8, AAV.PHPB, AAV. and is derived from an adeno-associated virus having a serotype selected from the group consisting of AV2.5, AAV2tYF, AAV3B, AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, AAV.HSC16, and AAVhu68. In some embodiments, the AAV vector or derivative thereof is a recombinant AAV (rAAV) vector, a hybrid AAV vector, a chimeric AAV vector, a single-stranded AAV (ss-AAV), a self-complementary AAV (scAAV) vector, or any combination thereof.
[0006] Also disclosed herein is a pharmaceutical composition comprising (a) an engineered guide RNA described herein, a polynucleotide described herein, or a delivery vehicle described herein, and (b) a pharmaceutically acceptable excipient, diluent, or carrier.
[0007] Also disclosed herein are methods of treating a disease in a subject in need thereof, the methods comprising administering to the subject an effective amount of an engineered guide RNA described herein, a polynucleotide described herein, a delivery vehicle described herein, or a pharmaceutical composition described herein, wherein the effective amount is sufficient to treat the disease in the subject. In some embodiments, the administering is intrathecal, intraocular, intravitreal, retinal, intravenous, intramuscular, intraventricular, intracerebral, intracerebellar, intraventricular, intraparenchymal, subcutaneous, or a combination thereof. In some embodiments, the disease is macular degeneration. In some embodiments, the disease is Stargardt's disease. In some embodiments, the disease comprises a neurological disease. In some embodiments, the neurological disease comprises Parkinson's disease, Alzheimer's disease, a tauopathy, or dementia. In some embodiments, the disease comprises a liver disease. In some embodiments, the liver disease comprises cirrhosis. In some embodiments, the liver disease comprises alpha-1 antitrypsin deficiency (AAT deficiency). In some embodiments, the target RNA is ABCA4. In some embodiments, ABCA4 comprises a target mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof. In some embodiments, the subject has been diagnosed with a disease.
[0008] Also disclosed herein is a method for improving the editing efficiency of an engineered guide RNA configured to facilitate editing of an adenosine in a target RNA via an RNA editing entity, wherein upon hybridization, the sequences of the engineered guide RNA and the target RNA form a guide-target RNA scaffold, the guide-target RNA scaffold comprising a region comprising at least one structural feature selected from the group consisting of a bulge, a wobble base pair, an internal loop, a mismatch, a hairpin, and any combination thereof, and wherein upon contacting the guide-target RNA scaffold with the RNA editing entity, the RNA editing entity modifies the guide-target RNA scaffold. and editing an on-target adenosine in a target RNA within the engineered guide RNA, the method comprising inserting a first sequence and a second sequence into the engineered guide RNA that form a first internal loop and a second internal loop, respectively, on opposite ends of a region of the guide-target RNA scaffold when the engineered guide RNA is hybridized to the target RNA, the first internal loop and the second internal loop facilitating an increased amount of editing of the on-target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop, thereby improving the editing efficiency of the engineered guide RNA.
[0009] Also disclosed herein are engineered guide RNAs described herein, polynucleotides described herein, delivery vehicles described herein, or pharmaceutical compositions described herein for use in treating diseases. In some embodiments, the agent is administered via intrathecal, intraocular, intravitreal, retinal, intravenous, intramuscular, intraventricular, intracerebellar, intracerebroventricular, intraparenchymal, or subcutaneous routes, or a combination thereof. In some embodiments, the disease is macular degeneration. In some embodiments, the disease is Stargardt's disease. In some embodiments, the disease comprises a neurological disease. In some embodiments, the neurological disease comprises Parkinson's disease, Alzheimer's disease, tauopathy, or dementia. In some embodiments, the disease comprises a liver disease. In some embodiments, the liver disease comprises cirrhosis. In some embodiments, the liver disease comprises alpha-1 antitrypsin deficiency (AAT deficiency). In some embodiments, the target RNA is ABCA4. In some embodiments, ABCA4 comprises a targeted mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof.
[0010] The novel features of the present disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments and the accompanying drawings. [Brief explanation of the drawings]
[0011] [Figure 1] Various guide RNA manipulations are shown: (1) microfootprint positioning, (2) microfootprint within macrofootprint (Left Bell coordinates: LB (generally with coordinates listed relative to mismatches); Right Bell coordinates: RB (generally with coordinates listed relative to mismatches), and (3) guide shortening. [Figure 2]An exemplary microfootprint is shown with complementary (+) and (-) RNA editing regions within the macrofootprint, each containing two internal symmetry loops flanking opposite ends of the microfootprint. The left / first internal symmetry loop is −6 bases from the target adenosine (AC) mismatch, while the right / second internal symmetry loop is +30 bases from the AC mismatch. [Figure 3] Figure 3 shows the guide-target RNA scaffolds formed by engineered ABCA4 RNA guides of various lengths edited by ADAR1. The 0.85.65 guide for both biological replicates exhibited an RNA editing percentage of approximately 15%. As shown in Figure 3, the 0.85.65 guide drives higher RNA editing efficiency and mediates specificity compared to the comparable guides screened in Figure 3. [Figure 4] Figure 1 shows various guide-target RNA scaffolds formed by engineered RNA guides, where the second internal symmetry loop (or right barbell) is positioned at various distances from the target adenosine to be edited, while the left barbell is left at position -5 relative to the mismatch. Guides 0.85.65 (-5, +33) and 0.85.65 (-5, +27) showed RNA editing percentages greater than approximately 15%. [Figure 5] ADAR profiles showing the ADAR-mediated RNA editing percentage for each of the engineered RNA guides (0.85.65(-5, +33) and 0.85.65(-5, +27)) and the control without the first and second internal symmetry loops (0.85.65) are shown. [Figure 6] Figure 1 shows various guide-target RNA scaffolds formed by 0.85 and 0.65 engineered RNA guides, with the first internal symmetry loop (or left bell) located at various distances from the mismatch. [Figure 7]Figure 1 shows various guide-target RNA scaffolds formed by engineered RNA guides, with the first internal symmetry loop (or left bell) positioned at various distances from the mismatch. Exemplary guides 0.85.65(-10, +33) and 0.85.65(-9, +33) show ADAR-mediated RNA editing percentages greater than approximately 30%. [Figure 8] Figure 1 shows the target position and ADAR-mediated RNA editing percentage for each of exemplary engineered RNA guides (0.85.65(-5, +33), 0.85.65(-9, +33), and 0.85.65(-10, +33)) where GAA is edited at the second base position identified as the zero target position, shown as "0" on the x-axis. Each of the exemplary guides exhibits an ADAR-mediated RNA editing percentage of greater than about 40% at the zero target position. [Figure 9] Specific biological replicates and average RNA editing percentages for various guide-target RNA scaffolds formed by ADAR-engineered RNA guides are shown, with exemplary guides having ADAR-mediated raw RNA editing percentages of about 20% or greater (e.g., 0.100.65, 0.100.67, 0.100.70, 0.100.72). As shown in Figure 9, mismatch positioning modulates RNA editing, with the 100.70 guide representing a superior configuration. [Figure 10] Figure 1 shows various guide-target RNA scaffolds formed by engineered RNA guides, with the second internal symmetry loop (or right bell) located at various distances from the mismatch based on guide 0.100.70. [Figure 11] Figure 1 shows exemplary guide-target RNA scaffolds formed by engineered RNA guides of edited ABCA4, where the second internal symmetry loop (or right bell) is positioned at various distances from the mismatch. Guide 0.100.70 (-5, +32) exhibited an ADAR-mediated RNA editing percentage greater than approximately 17%, the percentage of ADAR-mediated RNA editing for guide 0.100.70 without the first and second internal symmetry loops. [Figure 12]Figure 1 shows various guide-target RNA scaffolds formed by engineered RNA guides, with the first internal symmetry loop (or left bell) located at various distances from the mismatch based on guides 0.100.70. [Figure 13] Illustrated are exemplary guide-target RNA scaffolds formed by engineered RNA guides of edited ABCA4, with the first internal symmetry loop (or left bell) positioned at various distances from the mismatch. Exemplary guides 0.100.70(-5, +33), 0.100.70(-6, +33), 0.100.70(-9, +33), 0.100.70(-11, +33), 0.100.70(-12, +33), 0.100.70(-13, +33), 0.100.70(-14, +33), and 0.100.70(-15, +33) exhibit ADAR-mediated RNA editing percentages greater than approximately 34%, which is the ADAR-mediated RNA editing percentage of guide 0.100.70 without the first and second internal symmetry loops. [Figure 14] 1 shows the target position and percentage of ADAR-mediated RNA editing for each of exemplary engineered RNA guides 0.100.70(-5, +33), 0.100.70(-9, +33), 0.100.70(-13, +33), 0.100.70(-14, +33), and 0.100.70(-15, +33), without the first and second internal symmetry loops, where the edited base position is identified as the zero target position. Each of the exemplary guides, except for 0.100.70, exhibits a percentage of ADAR-mediated RNA editing of greater than about 30% at the zero target position or target 0 position. [Figure 15] Figure 1 shows an exemplary guide-target RNA scaffold formed by an engineered RNA guide of edited ABCA4 based on a first internal symmetry loop (LB) located -9 or -15 bases from the mismatch and a second internal symmetry loop (RB) located +33 bases from the mismatch, with the total length of the guide varied via precise deletion of 2 nt from the 5' end of the guide, as well as the length upstream of the mismatch (e.g., 0 position). [Figure 16]Figure 15 shows exemplary guide-target RNA scaffolds formed by engineered RNA guides, where the first internal symmetry loop (or left bell) and the second internal symmetry loop (or right bell) are maintained at positions -9 and +33, respectively, with varying lengths from mismatches. Exemplary guides 0.92.62 (-9, +33), 0.94.64 (-9, +33), and 0.96.66 (-9, +33) exhibited ADAR-mediated RNA editing percentages greater than about 38%, which is the RNA editing percentage of guide 0.100.70 (-9, +33). [Figure 17] The target position and percentage of ADAR-mediated raw RNA editing for each of exemplary engineered RNA guides 0.92.62 (-9, +33), 0.94.64 (-9, +33), and 0.96.66 (-9, +33), where the edited base position is identified as the zero target position, are shown. Each of the exemplary guides exhibits a percentage of ADAR-mediated RNA editing of greater than about 40% at the zero target position. [Figure 18] Figure 15 shows exemplary guide-target RNA scaffolds formed by engineered RNA guides, where the first internal symmetry loop (or left bell) and the second internal symmetry loop (or right bell) are maintained at positions -15 and +33, respectively, with varying lengths from the mismatch. Exemplary guides 0.90.60 (-15, +33), 0.92.62 (-15, +33), and 0.94.64 (-15, +33) exhibited ADAR-mediated RNA editing percentages greater than about 46%, which is the ADAR-mediated RNA editing percentage of guide 0.96.66 (-15, +33). [Figure 19] The target position and ADAR-mediated raw RNA editing percentage for each of exemplary engineered RNA guides 0.90.60(-15, +33), 0.92.62(-15, +33), and 0.94.64(-15, +33) are shown, where the edited base position is identified as the zero target position or target 0 position. Each of the exemplary guides exhibits an ADAR-mediated RNA editing percentage of greater than about 46% at the zero target position or target 0 position. [Figure 20]1 shows the target positions and ADAR-mediated RNA editing percentages for an exemplary engineered RNA guide before (guide without first and second internal loops 0.100.80) and after (guide with first and second internal loops 0.92.62(-15, +33)) improvement, where the edited base position is identified as the zero target position. The pre-improvement guide (0.100.80) exhibits an ADAR-mediated RNA editing percentage of approximately 12% at the zero target position, and the post-improvement guide (0.92.62(-15, +33)) exhibits an ADAR-mediated RNA editing percentage of approximately 58% at the zero target position. [Figure 21] Figure 1 shows exemplary guide-target RNA scaffolds formed by engineered RNA guides, where the target RNAs are ABCA4 (-9, +33) with the first and second internal loops and an AC mismatch (GAPDH 100.70 AC), GAPDH with a microfootprint GAPDH (GAPDH Shaker mimic), and GAPDH with the first and second internal loops (GAPDH Shaker mimic -9, +33). [Figure 22] Figure 21 shows the ADAR-mediated RNA editing percentage of the GAPDH engineered RNA guide and biological replicate controls (no transfection; GFP plasmid). The exemplary GAPDH RNA guide 0.100.70(-9, +33) exhibited an ADAR-mediated RNA editing percentage greater than about 25%, which is the ADAR-mediated RNA editing percentage of the GAPDH RNA guide 0.100.70(-9, +33). [Figure 23] Figure 21 shows the ADAR-mediated RNA editing percentages of GAPDH-engineered RNA guides. An exemplary GAPDH with an AC mismatch (top panel), a microfootprint (middle panel), and an exemplary GAPDH with the first and second internal loops (bottom panel) and a GAPDH-engineered RNA guide with a macrofootprint (bottom panel) show an ADAR-mediated RNA editing percentage of greater than about 20% at the zero target position. [Figure 24]1 shows an exemplary guide-target RNA scaffold formed by an engineered RNA guide, where the target RNA is Rab7a with an AC mismatch (Rab7a 100.70 AC; SEQ ID NO: 109), a microfootprint (Rab7a 100.70 Shaker mimic; SEQ ID NO: 110), and Rab7a with the first and second internal loops (Rab7a Shaker mimic -9, +33; SEQ ID NO: 111). [Figure 25] Figure 24 shows the ADAR-mediated RNA editing percentage of the Rab7a-engineered RNA guide and a biological replicate control (no transfection; GFP plasmid). The exemplary Rab7a RNA guide 0.100.70 (-9, +33) showed an ADAR-mediated RNA editing percentage of approximately 30%, while the control showed an ADAR-mediated RNA editing percentage of approximately 5%. [Figure 26] Figure 24 shows the target positions and ADAR-mediated RNA editing percentages of Rab7a-engineered RNA guides, where the edited base position is identified as the zero target position or target 0 position. The Rab7a Shaker-mimicking guide (0.100.70(-9, +33)) exhibits an ADAR-mediated RNA editing percentage of greater than about 20% at the zero target position, with fewer off-target edits. [Figure 27] 1 shows exemplary guide-target RNA scaffolds formed by engineered RNA guides in which the target RNAs are APP with an AC mismatch (APP 100.70 AC; SEQ ID NO: 112), a microfootprint (APP 100.70 Shaker mimic; SEQ ID NO: 113), and APP with the first and second internal loops (APP Shaker mimic -9, +33; SEQ ID NO: 114). [Figure 28] Figure 27 shows the ADAR-mediated RNA editing percentage of the APP-engineered RNA guide and biological replicate controls (no transfection; GFP plasmid). The exemplary APP RNA guide 0.100.70 (-9, +33) showed an ADAR-mediated RNA editing percentage of approximately 13%, and the control showed an ADAR-mediated RNA editing percentage of approximately 2%. [Figure 29]Figure 27 shows the target positions and ADAR-mediated RNA editing percentages of the APP-engineered RNA guides, where the edited base position is identified as the zero target position or target 0 position. The APP Shaker mimic guide (0.100.70(-9, +33)) shows an ADAR-mediated RNA editing percentage of greater than about 20% at the zero target position, with fewer off-target edits than the AC mismatch or Shaker mimic MAPT RNA guide. [Figure 30] Figure 1 shows an exemplary guide-target RNA scaffold formed by an engineered RNA guide in which the target RNA is MAPT with an AC mismatch (MAPT 100.70 AC), a microfootprint (MAPT 100.70 Shaker mimic), and MAPT with the first and second internal loops (MAPT Shaker mimic -9, +33). [Figure 31] Figure 30 shows the ADAR-mediated RNA editing percentage of the MAPT-engineered RNA guide and biological replicate controls (no transfection; GFP plasmid). The exemplary MAPT RNA guide 0.100.70 (-9, +33) showed an ADAR-mediated RNA editing percentage of greater than about 40%, while the control showed an ADAR-mediated RNA editing percentage of about 5%. [Figure 32] Figure 30 shows the target positions and ADAR-mediated RNA editing percentages of MAPT-engineered RNA guides, where the edited base position is identified as the zero target position or target 0 position. The MAPT Shaker-mimicking guide (0.100.70(-9, +33)) shows an ADAR-mediated RNA editing percentage of greater than about 40% at the zero target position, with fewer off-target edits than the AC mismatch or Shaker-mimicking MAPT RNA guide. [Figure 33] A summary of how the library was generated to screen for longer self-annealing RNA structures is shown. [Figure 34] 1 shows a comparison of cell-free RNA editing using the high-throughput techniques described herein with intracellular RNA editing facilitated via the same engineered guide RNA sequence at various time points. [Figure 35] Figure 1 shows a heat map of all self-annealing RNA structures tested for four microfootprints (A / C mismatches 2108, 871, and 919) formed within various configurations of the barbell macrofootprint. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 36]
[0023] Figure 1 shows a legend of various exemplary structural features present in the guide-target RNA scaffold formed upon hybridization of a potential guide RNA of the present disclosure to a target RNA. Exemplary structural features shown include an 8 / 7 asymmetric loop (8 nucleotides on the target RNA side and 7 nucleotides on the guide RNA side), a 2 / 2 symmetric bulge (2 nucleotides on the target RNA side and 2 nucleotides on the guide RNA side), a 1 / 1 mismatch (1 nucleotide on the target RNA side and 1 nucleotide on the guide RNA side), a 5 / 5 symmetric internal loop (5 nucleotides on the target RNA side and 5 nucleotides on the guide RNA side), a 24 bp region (24 nucleotides on the target RNA side base-paired with 24 nucleotides on the guide RNA side), and a 2 / 3 asymmetric bulge (2 nucleotides on the target RNA side and 3 nucleotides on the guide RNA side). [Figure 37] On-target editing (x-axis) versus specificity (y-axis) of various guide RNAs via ADAR for LRRK2 (far left), APP / GRN / SNCA (top row, left to right), and DUX4 / ABCA4 / SERPINA1 (bottom row, left to right) is shown. [Figure 38] 1 shows the LRRK2 RNA editing profiles of various engineered guide RNAs of the present disclosure mediated by ADAR. [Figure 39] 1 shows the LRRK2 ADAR-mediated RNA editing profile of engineered guide RNAs of the present disclosure that form barbell macro- and microfootprints in the guide target RNA scaffold. [Figure 40] A diagram of a strategy to minimize +1 editing by modulating the structure within the guide-target RNA complex is shown. [Figure 41]1 shows symmetric internal loop tiling within the guide-target RNA complex to minimize +1 editing. [Figure 42] We demonstrate the engineering of a guide to edit a target adenosine in ABCA4 with minimal +1 editing by exploiting a symmetric internal loop within the guide-target RNA complex. [Figure 43] 1 is a summary showing the progress of engineering candidate guide RNAs to minimize +1 editing by exploiting symmetric internal loops within the guide-target RNA complex. [Figure 44A] In an intracellular editing model, we demonstrate the ADAR-mediated RNA editing efficiency of machine learning-designed guide RNAs targeting LRRK2, each of which has a barbell macrofootprint with symmetric internal loops at positions -20 and +26. [Figure 44B] In an intracellular editing model, we demonstrate the ADAR-mediated RNA editing efficiency of machine learning-designed guide RNAs targeting LRRK2, each of which has a barbell macrofootprint with symmetric internal loops at positions -20 and +26. [Figure 44C] In an intracellular editing model, we demonstrate the ADAR-mediated RNA editing efficiency of machine learning-designed guide RNAs targeting LRRK2, each of which has a barbell macrofootprint with symmetric internal loops at positions -20 and +26. [Figure 45] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 for a control engineered guide and exemplary engineered guide 919. [Figure 46] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 for exemplary engineered guide 1976 and exemplary engineered guide 2397. [Figure 47] LRRK2-targeted RNA editing is shown for an exemplary engineered guide 871 and an exemplary engineered guide 610 via ADAR1 and ADAR1+ADAR2. [Figure 48]1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0703 and ML generation 0719 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 49] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0728 and ML generation 0732 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 50] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0733 and ML generation 0742 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 51] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0743 and ML generation 0745 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 52] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0766 and ML generation 0769 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 53] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0766 and ML generation 0769 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 54] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides MLExhaustive0049 and MLExhaustive0069 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 55] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides MLExhaustive0090 and MLExhaustive0139 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 56] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0274 and ML generation 0325 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 57] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0332 and ML generation 0559 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 58] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0639 and ML generation 0643 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 59] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0644 and ML generation 0690 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 60] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0699 and ML generation 0701 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 61] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML-exhaustive0395 and ML-exhaustive0453 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 62] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML exhaustive 0464 and ML exhaustive 1042 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 63] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0002 and ML generation 0013 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 64] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0016 and ML generation 0043 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 65]1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0058 and ML generation 0071 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 66] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0130 and ML generation 0156 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 67] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML generation 0176 and ML generation 0218 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 68] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides MLExhaustive1045 and MLExhaustive1540 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 69] 1 shows LRRK2-targeted RNA editing for exemplary engineered guides ML-exhaustive0315 and ML-exhaustive0414 designed by ADAR1 and ADAR1+ADAR2-mediated machine learning. [Figure 70] 1 shows LRRK2-targeted RNA editing for an exemplary engineered guide MLExhaustive0013 designed by machine learning via ADAR1 and ADAR1+ADAR2. [Figure 71A] A selection of two exemplary LRRK2 guide RNAs designed by machine learning is shown for further engineering. [Figure 71B] A selection of two exemplary LRRK2 guide RNAs designed by machine learning is shown for further engineering. [Figure 72] 1 shows plots of the editing specificity of LRRK2 exhaustive guide RNAs designed by machine learning via ADAR1, ADAR2, or ADAR1+ADAR2. [Figure 73] 1 shows exemplary LRRK2 exhaustive guide RNAs designed by machine learning that demonstrate specificity for ADAR2. [Figure 74A]Top performing guide RNAs showing specificity for ADAR1+ADAR2 are shown. [Figure 74B] Top performing guide RNAs showing specificity for ADAR1+ADAR2 are shown. [Figure 75A] Top performing guide RNAs that demonstrate specificity for ADAR2 are shown. [Figure 75B] Top performing guide RNAs that demonstrate specificity for ADAR2 are shown. [Figure 76A] Top performing guide RNAs that demonstrate specificity for ADAR1 are shown. [Figure 76B] Top performing guide RNAs that demonstrate specificity for ADAR1 are shown. [Figure 77] A comparison of ML-derived gRNAs with gRNAs generated using in vitro high-throughput screening (HTS) methods is shown. [Figure 78]
[0033] Figure 1 shows an overview of the engineering of guide RNAs produced from high-throughput screening. [Figure 79A] ADAR-mediated cell-free and intracellular editing of an exemplary LRRK2 guide 610 without (Figure 79A) and with (Figure 79B) a barbell macrofootprint is shown. [Figure 79B] ADAR-mediated cell-free and intracellular editing of an exemplary LRRK2 guide 610 without (Figure 79A) and with (Figure 79B) a barbell macrofootprint is shown. [Figure 80A]
[00103] Figure 80A shows the manipulation of macro footprint positioning for an exemplary guide 610 targeting LRRK2. Figure 80A shows the tiling of macro footprint positioning of an exemplary guide with respect to an A / C mismatch and how this tiling affects editing via ADAR1 and ADAR1 + ADAR2. Figure 80B shows the percentage editing of the ADAR1-mediated guide variant. Figure 80C shows the percentage editing of the ADAR1 + ADAR2-mediated guide variant. [Figure 80B]
[00103] Figure 80A shows the manipulation of macro footprint positioning for an exemplary guide 610 targeting LRRK2. Figure 80A shows the tiling of macro footprint positioning of an exemplary guide with respect to an A / C mismatch and how this tiling affects editing via ADAR1 and ADAR1 + ADAR2. Figure 80B shows the percentage editing of the ADAR1-mediated guide variant. Figure 80C shows the percentage editing of the ADAR1 + ADAR2-mediated guide variant. [Figure 80C]
[00103] Figure 80A shows the manipulation of macro footprint positioning for an exemplary guide 610 targeting LRRK2. Figure 80A shows the tiling of macro footprint positioning of an exemplary guide with respect to an A / C mismatch and how this tiling affects editing via ADAR1 and ADAR1 + ADAR2. Figure 80B shows the percentage editing of the ADAR1-mediated guide variant. Figure 80C shows the percentage editing of the ADAR1 + ADAR2-mediated guide variant. [Figure 81A] Figure 81A shows the manipulation of the right barbell coordinates for an exemplary guide 610 targeting LRRK2. As shown in Figure 81A, with respect to the A / C mismatch, the right barbell coordinates were tiled between the following coordinates: +22, +23, +24, +25, +26, +28, +30, +32, and +34 to determine the impact of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 81B shows the percent editing for an exemplary guide variant via ADAR1. Figure 81C shows the percent editing for an exemplary guide variant via ADAR1+ADAR2. [Figure 81B]Figure 81A shows the manipulation of the right barbell coordinates for an exemplary guide 610 targeting LRRK2. As shown in Figure 81A, with respect to the A / C mismatch, the right barbell coordinates were tiled between the following coordinates: +22, +23, +24, +25, +26, +28, +30, +32, and +34 to determine the impact of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 81B shows the percent editing for an exemplary guide variant via ADAR1. Figure 81C shows the percent editing for an exemplary guide variant via ADAR1+ADAR2. [Figure 81C] Figure 81A shows the manipulation of the right barbell coordinates for an exemplary guide 610 targeting LRRK2. As shown in Figure 81A, with respect to the A / C mismatch, the right barbell coordinates were tiled between the following coordinates: +22, +23, +24, +25, +26, +28, +30, +32, and +34 to determine the impact of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 81B shows the percent editing for an exemplary guide variant via ADAR1. Figure 81C shows the percent editing for an exemplary guide variant via ADAR1+ADAR2. [Figure 82A] Figure 82A shows the manipulation of the left barbell coordinate for an exemplary guide targeting LRRK2. As shown in Figure 82A, with respect to the A / C mismatch, the left barbell coordinate was tiled between the following coordinates: -10, -12, -14, -16, -18, -20, -22, and -24, and the effect of each position on ADAR1 and ADAR1 + ADAR2 editing was determined. Figure 82B shows the percent editing for an exemplary guide variant via ADAR1. [Figure 82B] Figure 82A shows the manipulation of the left barbell coordinate for an exemplary guide targeting LRRK2. As shown in Figure 82A, with respect to the A / C mismatch, the left barbell coordinate was tiled between the following coordinates: -10, -12, -14, -16, -18, -20, -22, and -24, and the effect of each position on ADAR1 and ADAR1 + ADAR2 editing was determined. Figure 82B shows the percent editing for an exemplary guide variant via ADAR1. [Figure 83A] Figure 83A shows the effect of guide length on ADAR1 and ADAR1+ADAR2 editing. Figure 83B shows percent editing for exemplary guide variants of various lengths via ADAR1. The y-axis shows the engineered guide RNAs of all candidate tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 83B] Figure 83A shows the effect of guide length on ADAR1 and ADAR1+ADAR2 editing. Figure 83B shows percent editing for exemplary guide variants of various lengths via ADAR1. The y-axis shows the engineered guide RNAs of all candidate tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 84A] Figure 84 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2063 variants without (Figure 84A) and with (Figure 84B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 84B] Figure 84 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2063 variants without (Figure 84A) and with (Figure 84B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 85A] Figure 85 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1590 variants without (Figure 85A) and with (Figure 85B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 85B] Figure 85 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1590 variants without (Figure 85A) and with (Figure 85B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 86A] Figure 86 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2397 variants without (Figure 86A) and with (Figure 86B and Figure 86C) barbells via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 86B] Figure 86 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2397 variants without (Figure 86A) and with (Figure 86B and Figure 86C) barbells via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 86C] Figure 86 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2397 variants without (Figure 86A) and with (Figure 86B and Figure 86C) barbells via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 87A]
[00130] Figure 87A shows a summary of the RNA editing efficiency for the exemplary guide 2397 RNA variant, while Figures 87B and 87C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 87B) and ADAR1 + ADAR2 (Figure 87C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 87B]
[00130] Figure 87A shows a summary of the RNA editing efficiency for the exemplary guide 2397 RNA variant, while Figures 87B and 87C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 87B) and ADAR1 + ADAR2 (Figure 87C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 87C]
[00130] Figure 87A shows a summary of the RNA editing efficiency for the exemplary guide 2397 RNA variant, while Figures 87B and 87C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 87B) and ADAR1 + ADAR2 (Figure 87C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 88A] Figure 88A shows the right barbell coordinates for the exemplary guide 2397 RNA variants. Figure 88A shows a summary of RNA editing efficiency for the exemplary guide 2397 RNA variants, while Figures 88B and 88C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 88B) and ADAR1 + ADAR2 (Figure 88C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 88B]Figure 88A shows the right barbell coordinates for the exemplary guide 2397 RNA variants. Figure 88A shows a summary of RNA editing efficiency for the exemplary guide 2397 RNA variants, while Figures 88B and 88C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 88B) and ADAR1 + ADAR2 (Figure 88C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 88C] Figure 88A shows the right barbell coordinates for the exemplary guide 2397 RNA variants. Figure 88A shows a summary of RNA editing efficiency for the exemplary guide 2397 RNA variants, while Figures 88B and 88C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 88B) and ADAR1 + ADAR2 (Figure 88C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 89] 10 shows the operation of the left barbell coordinate for the exemplary guide 2397 RNA variant. [Figure 90A] Figure 90 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1321 variants without (Figure 90A) and with (Figure 90B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 90B] Figure 90 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1321 variants without (Figure 90A) and with (Figure 90B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 91A]Figure 91A shows ADAR1- and ADAR1+ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 295 variants without (Figure 91A) and with (Figure 91B) a barbell. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 91B] Figure 91A shows ADAR1- and ADAR1+ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 295 variants without (Figure 91A) and with (Figure 91B) a barbell. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 92A] Figure 92A shows ADAR1- and ADAR1+ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 730 variants without (Figure 92A) and with (Figure 92B) a barbell. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 92B] Figure 92A shows ADAR1- and ADAR1+ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 730 variants without (Figure 92A) and with (Figure 92B) a barbell. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 93A] Figure 93 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 708 variants without (Figure 93A) and with (Figure 93B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 93B]Figure 93 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 708 variants without (Figure 93A) and with (Figure 93B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 94A] Figure 94 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA351 variants without (Figure 94A) and with (Figure 94B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 94B] Figure 94 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA351 variants without (Figure 94A) and with (Figure 94B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 95A] Figure 95 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1326 variants without (Figure 95A) and with (Figure 95B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 95B] Figure 95 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1326 variants without (Figure 95A) and with (Figure 95B) a barbell via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96A]Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96B] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96C] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96D] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96E] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96F]Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96G] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96H] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96I] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96J] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96K]Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96L] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96M] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96N] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 96O] Figure 96 shows ADAR1 and ADAR1 + ADAR2-mediated intracellular and cell-free editing of LRRK2 by exemplary guide RNA 871 variants without (Figure 96A) and with (Figure 96B-Figure 96O) barbells. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 97A]
[00130] Figure 97A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 97B and 97C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 97B) and ADAR1 + ADAR2 (Figure 97C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 97B]
[00130] Figure 97A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 97B and 97C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 97B) and ADAR1 + ADAR2 (Figure 97C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 97C]
[00130] Figure 97A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 97B and 97C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 97B) and ADAR1 + ADAR2 (Figure 97C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 98A] Figure 98A shows the right barbell coordinates for the exemplary guide 871 RNA variant. Figure 98A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figure 98B and Figure 98C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 98B) and ADAR1 + ADAR2 (Figure 98C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 98B] Figure 98A shows the right barbell coordinates for the exemplary guide 871 RNA variant. Figure 98A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figure 98B and Figure 98C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 98B) and ADAR1 + ADAR2 (Figure 98C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 98C] Figure 98A shows the right barbell coordinates for the exemplary guide 871 RNA variant. Figure 98A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figure 98B and Figure 98C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 98B) and ADAR1 + ADAR2 (Figure 98C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 99A] Figure 99A shows the left barbell coordinates for the exemplary guide 871 RNA variant. Figure 99A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 99B and 99C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 99B) and ADAR1 + ADAR2 (Figure 99C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 99B] Figure 99A shows the left barbell coordinates for the exemplary guide 871 RNA variant. Figure 99A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 99B and 99C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 99B) and ADAR1 + ADAR2 (Figure 99C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 99C]Figure 99A shows the left barbell coordinates for the exemplary guide 871 RNA variant. Figure 99A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 99B and 99C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 99B) and ADAR1 + ADAR2 (Figure 99C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 100A]
[00130] Figure 100A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 100B and 100C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 100B) and ADAR1 + ADAR2 (Figure 100C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 100B]
[00130] Figure 100A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 100B and 100C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 100B) and ADAR1 + ADAR2 (Figure 100C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 100C]
[00130] Figure 100A shows a summary of the RNA editing efficiency for the exemplary guide 871 RNA variant, while Figures 100B and 100C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 100B) and ADAR1 + ADAR2 (Figure 100C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101A]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101B] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101C] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101D]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101E] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101F] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101G]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101H] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101I] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101J]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101K] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101L] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101M]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101N] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101O] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101P]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101Q] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101R] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101S]Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 101T] Figure 101A shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. Figure 101A provides a summary of intracellular editing data for exemplary guide 919 variants via ADAR1 and ADAR1+ADAR2. Figures 101B-101T show positional editing efficiency for each exemplary guide 919 RNA via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 102A]
[00130] Figure 102A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 102B and 102C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 102B) and ADAR1 + ADAR2 (Figure 102C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 102B]
[00130] Figure 102A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 102B and 102C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 102B) and ADAR1 + ADAR2 (Figure 102C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 102C]
[00130] Figure 102A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 102B and 102C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 102B) and ADAR1 + ADAR2 (Figure 102C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 103A] Figure 103A shows a summary of RNA editing efficiencies for the exemplary guide 919 RNA variants, while Figures 103B and 103C show the positional editing efficiencies for each exemplary guide RNA via ADAR1 (Figure 103B) and ADAR1+ADAR2 (Figure 103C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 103B] Figure 103A shows a summary of RNA editing efficiencies for the exemplary guide 919 RNA variants, while Figures 103B and 103C show the positional editing efficiencies for each exemplary guide RNA via ADAR1 (Figure 103B) and ADAR1+ADAR2 (Figure 103C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 103C] Figure 103A shows a summary of RNA editing efficiencies for the exemplary guide 919 RNA variants, while Figures 103B and 103C show the positional editing efficiencies for each exemplary guide RNA via ADAR1 (Figure 103B) and ADAR1+ADAR2 (Figure 103C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 104A] Figure 104A shows the left barbell coordinates for the exemplary guide 919 RNA variants. Figure 104A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variants, while Figure 104B and Figure 104C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 104B) and ADAR1 + ADAR2 (Figure 104C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 104B] Figure 104A shows the left barbell coordinates for the exemplary guide 919 RNA variants. Figure 104A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variants, while Figure 104B and Figure 104C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 104B) and ADAR1 + ADAR2 (Figure 104C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 104C]Figure 104A shows the left barbell coordinates for the exemplary guide 919 RNA variants. Figure 104A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variants, while Figure 104B and Figure 104C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 104B) and ADAR1 + ADAR2 (Figure 104C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 105A]
[00130] Figure 105A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 105B and 105C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 105B) and ADAR1 + ADAR2 (Figure 105C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 105B]
[00130] Figure 105A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 105B and 105C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 105B) and ADAR1 + ADAR2 (Figure 105C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 105C]
[00130] Figure 105A shows a summary of the RNA editing efficiency for the exemplary guide 919 RNA variant, while Figures 105B and 105C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 105B) and ADAR1 + ADAR2 (Figure 105C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 106A] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 106B] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 106C] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 107A] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 107B] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 107C] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 108A]
[00130] Figure 108A shows a summary of the RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 108B and 108C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 108B) and ADAR1 + ADAR2 (Figure 108C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 108B]
[00130] Figure 108A shows a summary of the RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 108B and 108C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 108B) and ADAR1 + ADAR2 (Figure 108C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 108C]
[00130] Figure 108A shows a summary of the RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 108B and 108C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 108B) and ADAR1 + ADAR2 (Figure 108C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 109A]Figure 109A shows a summary of RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 109B and 109C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 109B) and ADAR1+ADAR2 (Figure 109C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 109B] Figure 109A shows a summary of RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 109B and 109C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 109B) and ADAR1+ADAR2 (Figure 109C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 109C] Figure 109A shows a summary of RNA editing efficiency for the exemplary guide 1976 RNA variant, while Figures 109B and 109C show the positional editing efficiency for each exemplary guide RNA via ADAR1 (Figure 109B) and ADAR1+ADAR2 (Figure 109C). The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the edited target adenosine. [Figure 110] 1 shows the operation of the left barbell coordinate for the exemplary guide 1976 RNA variant. [Figure 111] Figure 17 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 1700. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 112A]Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 860 variants. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 112B] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 860 variants. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 112C] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 860 variants. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 112D] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 860 variants. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 112E] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 860 variants. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 113] Figure 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2108. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 114] 1 shows a comparison of editing efficiency between exemplary guide RNA variants targeting LRRK2. [Figure 115] 1 shows a scAAV vector map for in vitro screening of the LRRK2 guide RNA variants produced herein when expressed in an AAV vector. [Figure 116A]116A shows the editing efficiency of an exemplary LRRK2 guide provided herein when transfected as a scAAV vector plasmid (FIG. 116A) or transduced as a scAAVDJ virus via ADAR (FIG. 116B). [Figure 116B] 116A shows the editing efficiency of an exemplary LRRK2 guide provided herein when transfected as a scAAV vector plasmid (FIG. 116A) or transduced as a scAAVDJ virus via ADAR (FIG. 116B). [Figure 117A] 1 shows editing of ABCA4 mRNA using an exemplary guide RNA as described herein via ADAR. [Figure 117B] 1 shows editing of ABCA4 mRNA using an exemplary guide RNA as described herein via ADAR. [Figure 118] 1 shows an exemplary guide RNA that can facilitate ADAR-mediated editing of a target adenosine in ABCA4 mRNA that has a 5′ G next to the target adenosine. [Figure 119] Tiling of barbell macrofootprint positions along the guide-target RNA scaffold to identify engineered guide RNAs that facilitate the highest levels of SERPINA1 editing is shown. [Figure 120] 1 shows the design of right and left barbell coordinates and manipulation of guide length for an exemplary engineered guide 06566RNA. [Figure 121] 1 shows intracellular ADAR-mediated editing of an exemplary engineered guide RNA targeting SERPINA1 using GFP editing report screening. The y-axis shows all candidate engineered guide RNAs tested, and the x-axis shows the target sequence position, with position 0 representing the target adenosine being edited. [Figure 122] 1 shows ADAR-mediated editing efficiency for an exemplary engineered guide SERP-AC-AA_95-50_-10_25 targeting SERPINA1. [Figure 123]1 shows ADAR-mediated editing efficiency for an exemplary engineered guide SERP-AC-AA_95-50_-8_28 targeting SERPINA1. [Figure 124] 1 shows ADAR-mediated editing efficiency for an exemplary engineered guide SERP-AC-AA_95-50_-10_26 targeting SERPINA1. [Figure 125] 1 shows ADAR-mediated editing efficiency for an exemplary engineered guide SERP-100.50-position_-20 adenosine scan control targeting SERPINA1. [Figure 126] 1 shows ADAR1-mediated editing efficiency for an exemplary engineered guide-encoding AAV vector targeting ABCA4 G1961E in human cells. [Figure 127] Figure 1 shows a workflow for screening exemplary guide RNAs targeting LRRK2 in a disrupted GFP reporter system. [Figure 128] Figure 1 shows the editing efficiency of exemplary guides targeting LRRK2 in a disrupted GFP reporter system via exogenous or endogenous ADARs. [Figure 129] 1 shows the change in body weight for subjects administered an AAV vector encoding an exemplary engineered guide RNA targeting SERPINA1 and a control vector over the course of a 28-day study. [Figure 130] 1 shows transduction of engineered guide RNA payloads in the liver following administration of an AAV vector encoding an exemplary engineered guide RNA targeting SERPINA1 and a control vector, as measured by expression of the mCherry reporter. [Figure 131] 1 shows normalized quantification of engineered guide RNAs following administration of an AAV vector encoding an exemplary engineered guide RNA targeting SERPINA1 and a control vector. [Figure 132]Quantification of the amount of ADAR-mediated targeted adenosine editing of SERPINA1 RNA upon administration of an AAV vector encoding an engineered guide RNA targeting SERPINA1, compared to the editing level of a control AAV vector. [Figure 133] 1 provides a comparison between linear and circularized versions of exemplary guide RNAs targeting LRRK2. [Figure 134A] Figure 134 shows manipulation of the length of the circularized LRRK2 guide RNA by increasing the length of the circularized LRRK2 guide RNA by an additional 15 nucleotides (Figure 134A), 30 nucleotides (Figure 134A), and 100 nucleotides (Figure 134B). [Figure 134B] Figure 134 shows manipulation of the length of the circularized LRRK2 guide RNA by increasing the length of the circularized LRRK2 guide RNA by an additional 15 nucleotides (Figure 134A), 30 nucleotides (Figure 134A), and 100 nucleotides (Figure 134B). [Figure 135] 1 shows the effect of deleting selected uridines from engineered circularized guide RNAs targeting target LRRK2 on editing of the target LRRK2 RNA. [Figure 136A] Figure 136A and Figure 136C show the in vivo editing of target LRRK2 RNA upon administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2, as measured in the brain (Figure 136A) and liver (Figure 136C). Figure 136B and Figure 136D show quantification of engineered guide RNA expression relative to GAPDH control expression in the brain (Figure 136B) and liver (Figure 136D). [Figure 136B]Figure 136A and Figure 136C show the in vivo editing of target LRRK2 RNA upon administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2, as measured in the brain (Figure 136A) and liver (Figure 136C). Figure 136B and Figure 136D show quantification of engineered guide RNA expression relative to GAPDH control expression in the brain (Figure 136B) and liver (Figure 136D). [Figure 136C] Figure 136A and Figure 136C show the in vivo editing of target LRRK2 RNA upon administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2, as measured in the brain (Figure 136A) and liver (Figure 136C). Figure 136B and Figure 136D show quantification of engineered guide RNA expression relative to GAPDH control expression in the brain (Figure 136B) and liver (Figure 136D). [Figure 136D] Figure 136A and Figure 136C show the in vivo editing of target LRRK2 RNA upon administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2, as measured in the brain (Figure 136A) and liver (Figure 136C). Figure 136B and Figure 136D show quantification of engineered guide RNA expression relative to GAPDH control expression in the brain (Figure 136B) and liver (Figure 136D). [Figure 137] 1 shows the results of a library screen of SERPINA1 targeting guides. Edited ADAR1 fraction is shown on the Y-axis and specificity score is shown on the X-axis. DETAILED DESCRIPTION OF THE INVENTION
[0012] Guided Operation Using Barbell Macro Footprint Disclosed herein is an engineered guide RNA for site-specific editing of adenosine in a target RNA via adenosine deaminase enzyme. The engineered guide RNA of the present disclosure comprises a microfootprint sequence and a barbell macrofootprint sequence, each of which contains a potential structure, such that the potential structure is revealed when the engineered guide RNA is hybridized to the target RNA. When revealed, the potential structure generates at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a hairpin, and any combination thereof. In some embodiments, engineered guide RNAs of the present disclosure, upon hybridization of the engineered guide RNA and target RNA sequences, form a guide-target RNA scaffold that includes (i) a region comprising at least one structural feature, and (ii) a first internal loop (also referred to as a "left bell" or "LB") and a second internal loop (also referred to as a "right bell" or "RB") adjacent to opposite ends of the guide-target RNA scaffold region, wherein the engineered guide RNA facilitates an increased amount of targeted editing of adenosines in the target RNA via an adenosine deaminase enzyme RNA editing entity compared to an otherwise equivalent engineered guide RNA lacking the first and second internal loops.
[0013] As described herein, a "microfootprint" sequence refers to a sequence that, when present, has a potential structure that facilitates the editing of adenosines in a target RNA via adenosine deaminase enzymes. The macrofootprint can serve to guide RNA-editing entities (e.g., ADARs) and direct their activity toward the microfootprint. In some embodiments, the microfootprint sequence includes a nucleotide positioned such that, when the guide RNA is hybridized to the target RNA, the nucleotide faces the adenosine to be edited by adenosine deaminase and does not base-pair with the edited adenosine. This nucleotide, referred to herein as a "mismatch position" or "mismatch," may be a cytosine. The microfootprint sequences described herein have at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a hairpin, and any combination thereof, upon hybridization of the engineered guide RNA and the target RNA. Engineered guide RNAs with excellent microfootprint sequences can be selected based on their ability to facilitate editing of a specific target RNA. Engineered guide RNAs, selected for their ability to facilitate editing of specific targets, can adopt a variety of microfootprint potential structures that can vary on a target-by-target basis.
[0014] The guide RNA of the present disclosure further comprises a macrofootprint. In some embodiments, the macrofootprint comprises a barbell macrofootprint. The microfootprint can serve to guide and direct the activity of an RNA-editing enzyme to the target adenosine to be edited. As used herein, "barbell" refers to a pair of potential internal loop structures that appear upon hybridization of the guide RNA to the target RNA. In some embodiments, each internal loop is positioned toward the 5' or 3' end of the guide-target RNA scaffold formed upon hybridization of the guide RNA and the target RNA. In some embodiments, each internal loop is adjacent to opposite sides of a microfootprint sequence. Upon hybridization of the guide RNA to the target RNA, insertion of barbell macrofootprint sequences adjacent to opposite sides of the microfootprint sequence results in the formation of a barbell internal loop on the opposite side of the microfootprint, which then contains at least one structural feature that facilitates editing of the specific target RNA.
[0015] The present disclosure demonstrates that the presence of a barbell adjacent to a microfootprint can improve one or more aspects of editing. For example, the presence of a barbell macrofootprint in addition to a microfootprint can result in a greater amount of on-target adenosine editing compared to an otherwise equivalent guide RNA lacking the barbell. Additionally and / or alternatively, the presence of a barbell macrofootprint in addition to a microfootprint can result in a lesser amount of localized off-target adenosine editing compared to an otherwise equivalent guide RNA lacking the barbell. Furthermore, while the effects of various microfootprint structural features may vary on a target-by-target basis based on selection in high-throughput screens, the present disclosure demonstrates that the enhancement of one or more aspects of editing provided by the barbell macrofootprint structure is independent of the specific target RNA. Thus, the present disclosure provides a facile method for improving editing of previously selected guide RNAs to facilitate editing of a target RNA of interest. For example, the barbell macrofootprints and microfootprints of the present disclosure can provide increased amounts of on-target adenosine editing compared to an otherwise equivalent guide RNA lacking the barbell. In other embodiments, the presence of a barbell macrofootprint in addition to the microfootprints described herein may result in a lower amount of localized off-target adenosine editing upon hybridization of a guide RNA and a target RNA to form a guide-target RNA scaffold lacking the barbell, compared to an otherwise equivalent guide RNA.
[0016] The macrofootprints of the present disclosure, such as the barbell macrofootprint, can be included in engineered guide RNAs designed to target any number of target RNAs, including, but not limited to, ABCA4, APP, CFTR, DMPK, DUX4, GAPDH, GBA, GRN, HEXA, LIPA, LRRK2, MAPT, PINK1, PMP22, RAB7A, SERPINA1, SNCA, SOD1, fragments of any one of these, and any combination thereof.
[0017] Engineered guide RNAs Provided herein are engineered guide RNAs (and engineered polynucleotides encoding the engineered guide RNAs of the present disclosure) that contain microfootprint and barbell macrofootprint sequences for site-specific editing of target RNAs via adenosine deaminase enzymes. As used herein, the term "engineered," with respect to a guide RNA or a polynucleotide encoding it, refers to a non-natural guide RNA or a polynucleotide encoding it. The engineered guide RNAs disclosed herein include a targeting domain that has complementarity to the target RNA, and hybridization of the targeting domain of the engineered guide RNA to the target RNA generates potential structures within the guide-target RNA scaffold that appear upon hybridization to the structural features described herein. The "guide-target RNA scaffolds" described herein may also be referred to as "double-stranded RNA substrates." As disclosed herein, inclusion of a barbell macrofootprint sequence in the targeting domain to generate a pair of internal loop structural features flanking the microfootprint sequence improves one or more aspects of editing compared to an otherwise equivalent guide RNA lacking the barbell macrofootprint sequence (and thus the pair of internal loop structural features).
[0018] Barbell Macro Footprint Disclosed herein are barbell macrofootprint sequences that, upon hybridization to a target RNA, generate a pair of internal loop structural features, the presence of which improves one or more aspects of editing compared to an otherwise equivalent guide RNA lacking the pair of internal loop structural features. In some examples, the inclusion of a barbell macrofootprint sequence improves the amount of editing of an adenosine of interest (e.g., an on-target adenosine) compared to the amount of editing of an on-target adenosine in an equivalent guide RNA lacking the barbell macrofootprint sequence. In some examples, the inclusion of a barbell macrofootprint sequence reduces the amount of editing of adenosines other than the adenosine of interest (e.g., reduces off-target adenosines) compared to the amount of off-target adenosines in an equivalent guide RNA lacking the barbell macrofootprint sequence.
[0019] As disclosed herein, a "macro footprint" sequence can be positioned such that it is adjacent to a micro footprint sequence. Additionally, a macro footprint sequence can be adjacent to a micro footprint sequence, but can also incorporate additional potential structures adjacent to either end of the macro footprint. In some embodiments, such additional potential structures are included as part of the macro footprint. In some embodiments, such additional potential structures are separate, distinct, or both separate and distinct from the macro footprint.
[0020] In some embodiments, the macro footprint sequence may include a barbell macro footprint sequence that includes potential structures that, when encountered, generate a first inner loop and a second inner loop.
[0021] In some examples, the first internal loop is located "near the 5' end of the guide-target RNA scaffold," and the second internal loop is located near the 3' end of the guide-target RNA scaffold. The length of the dsRNA includes the 5' end and the 3' end, and up to half of the length of the guide-target RNA scaffold at the 5' end can be considered "near the 5' end," and up to half of the length of the guide-target RNA scaffold at the 3' end can be considered "near the 3' end." Non-limiting examples of the 5' end can include about 50% or less, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of the total length of the dsRNA at the 5' end. Non-limiting examples of the 3' end can include about 50% or less, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of the total length of the dsRNA at the 3' end.
[0022] Engineered guide RNAs of the present disclosure that include a barbell macrofootprint sequence (appearing as a first internal loop and a second internal loop) can improve RNA editing efficiency and generally increase the amount or percentage of RNA editing and on-target nucleotide edits, such as on-target adenosine. In some embodiments, engineered guide RNAs of the present disclosure that include a first internal loop and a second internal loop can also facilitate a reduction in the amount of off-target nucleotide edits, such as off-target adenosine or unintended adenosine edits, or can reduce off-target nucleotide edits. In some examples, the reduction can refer to the number of off-target edits or the percentage of off-target edits.
[0023] Each of the first and second internal loops of the barbell macrofootprint can independently be symmetric or asymmetric, with the symmetry determined by the number of bases or nucleotides in the engineered guide RNA and the number of bases or nucleotides in the target RNA that together form each of the first and second internal loops.
[0024] As described herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. A "symmetric internal loop" is formed when the same number of nucleotides are present on both sides of the internal loop. For example, a symmetric internal loop of a guide-target RNA scaffold of the present disclosure can have the same number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. The symmetric internal loops of the present disclosure may be designated as 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, 20 / 20, etc., symmetric internal loops, where the first number is the number of nucleotides contributed to the symmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the symmetric internal loop from the target RNA side of the guide-target RNA scaffold. The symmetric internal loops of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 5 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loops of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 8 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 9 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 10 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 15 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 15 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 20 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 20 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 30 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 30 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 40 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 40 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 50 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 60 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 60 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 70 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 70 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 80 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 80 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 90 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 90 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 100 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure can be formed by 110 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 110 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 120 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 120 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 130 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 130 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 140 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 140 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 150 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 200 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 250 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 250 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 300 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 350 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 350 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 400 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 450 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 450 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 500 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 600 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 600 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 700 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 700 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 800 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 800 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 900 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 900 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 1000 nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, a symmetric internal loop can be a structural feature formed from a potential structure provided by a potential engineered guide RNA.
[0025] As described herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. An "asymmetric internal loop" is formed when a different number of nucleotides is present on both sides of the internal loop. For example, the asymmetric internal loop of a guide-target RNA scaffold of the present disclosure can have a different number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold.
[0026] The asymmetric inner loops of the present disclosure are: 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 14 / 10, 14 / 11, 14 / 12, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14, 15 / 16, 15 / 17, 15 / 18, 15 / 19, 15 / 20, 16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10,17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / The asymmetric internal loop may be designated as 20, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, 20 / 19, etc., where the first number is the number of nucleotides contributed to the asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and the second number is the number of nucleotides contributed to the asymmetric internal loop from the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 to 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5 to 150 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold is different from the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 to 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5 to 1000 nucleotides on the target RNA side of the guide-target RNA scaffold, wherein the number of nucleotides on the engineered side of the guide-target RNA scaffold is different compared to the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can beThe asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target ... The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 10-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 7-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of an 8-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can beThe asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 9-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 10-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of an 8-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 7 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 9-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 7 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 10-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 7 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed byThe asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 9-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 10-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and the target RNA side of a 10-nucleotide internal loop of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 9 nucleotides on the target ... 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed byThe asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1,000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1,000 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 30 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 0 nucleotides. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. Thus, the asymmetric internal loop can be a structural feature formed from a potential structure provided by a potential engineered guide RNA.
[0027] In some embodiments, the first internal loop or the second internal loop, independently, is at least about 5 bases or more (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150), and up to about 150 bases (e.g., 145, 135, 125, 115, 95, 85, 75, 65 ... of the engineered guide RNA. 5, 45, 35, 25, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5), or at least about 5 bases to at least about 150 bases (e.g., 5-150, 6-145, 7-140, 8-135, 9-130, 10-125, 11-120, 12-115, 13-110, 14-105, 15-100, 16-95, 17-90, 18-85, 19-80, 20-75, 21-70, 22-65, 23-66, 24-68, 25-70, 26-75, 27-80, 28-95, 29-105, 30-310, 31-320, 32-330, 33-340, 34-350, 35-360, 36-370, 37-380, 38-400, 39-410, 42-430, 43-440, 44-450, 45-460, 46-470, 47-480, 48-490, 49-500, 50-510, 51-520, 52-530, 53-540, 54-550, 55-560, 56-570, 57-580, 58-590, 59-600, 60-610, 61 3 to 60, 24 to 55, 25 to 50) and at least about 5 bases or more of the target RNA (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150), about 150 bases or less (e.g., 145, 135, 125, 115, 95, 85, 75, 65, 55, 45, 35, 25, 19, 18, 17, 16, 15, The number of bases may range from about 5 to about 150 (e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5), or from about 5 to about 150 (e.g., 5 to 150, 6 to 145, 7 to 140, 8 to 135, 9 to 130, 10 to 125, 11 to 120, 12 to 115, 13 to 110, 14 to 105, 15 to 100, 16 to 95, 17 to 90, 18 to 85, 19 to 80, 20 to 75, 21 to 70, 22 to 65, 23 to 60, 24 to 55, 25 to 50).
[0028] In some embodiments, an engineered guide RNA comprising a barbell macrofootprint (e.g., a potential structure appearing as a first internal loop and a second internal loop) comprises a cytosine in a microfootprint sequence between the macrofootprint sequences present in the guide-target RNA scaffold opposite the adenosine (e.g., on-target adenosine) edited by the RNA editing entity when the engineered guide RNA is hybridized to the target RNA. In such embodiments, the cytosine in the microfootprint is included in an A / C mismatch with the on-target adenosine of the target RNA in the guide-target RNA scaffold.
[0029] The first and second internal loops of the barbell macrofootprint can be positioned a certain distance from the A / C mismatch relative to the bases of the first and second internal loops that are closest to the A / C mismatch. In some embodiments, the first and second internal loops can be positioned the same number of bases from the A / C mismatch relative to the bases of the first and second internal loops that are closest to the A / C mismatch. In some embodiments, the first and second internal loops can be positioned a different number of bases from the A / C mismatch relative to the bases of the first and second internal loops that are closest to the A / C mismatch.
[0030] In some embodiments, the barbell first internal loop or the barbell second internal loop can be positioned at least about 5 bases (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) away from the A / C mismatch relative to the base of the first internal loop or second internal loop closest to the A / C mismatch. In some embodiments, the barbell first internal loop or the barbell second internal loop can be positioned up to about 50 bases (e.g., 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5) away from the A / C mismatch relative to the base of the first internal loop or second internal loop closest to the A / C mismatch.
[0031] In some embodiments, the first internal loop can be positioned about 1 base from the A / C mismatch to about 30 bases (e.g., 1-20, 7-30, 5-20, 6-20, 5-15) away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 5 bases from the A / C mismatch to about 15 bases (e.g., 5-15, 6-14, 7-13, 8-12, 9-11) away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some examples, the first internal loop can be positioned about 9 bases from the A / C mismatch to about 15 bases (e.g., 10-14, 11-13) away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch.
[0032] In some embodiments, the second internal loop can be positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch (e.g., 13-39, 14-38, 15-40, 15-38, 15-37, 16-36, 17-35, 18-38, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27) relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 20 bases from the A / C mismatch to about 33 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned 24, 26, 28, or 30 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned at least about 1 base away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned about 1 base away from the on-target adenosine of the target RNA to about 30 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned about 1 base away from the on-target adenosine of the target RNA to about 20 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned at least about 5 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned about 5 bases away from the on-target adenosine of the target RNA to about 15 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned at least about 6 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned from about 6 bases away from the on-target adenosine of the target RNA to about 20 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned at least about 7 bases away from the on-target adenosine of the target RNA.In some embodiments, the first internal loop can be positioned between about 7 bases from the on-target adenosine of the target RNA and about 30 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned between about 9 bases from the on-target adenosine of the target RNA and about 15 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned between about 6 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned between about 10 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned between about 12 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned between about 15 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned at least about 12 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned between about 12 bases from the on-target adenosine of the target RNA and about 40 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned at least about 15 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned between about 15 bases from the on-target adenosine of the target RNA and about 40 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned between about 15 bases from the on-target adenosine of the target RNA and about 38 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned at least about 18 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned between about 18 bases from the on-target adenosine of the target RNA and about 38 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned from about 18 bases away from the on-target adenosine of the target RNA to about 35 bases away from the on-target adenosine of the target RNA.In some embodiments, the second internal loop can be positioned about 20 bases from the on-target adenosine of the target RNA to about 33 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned about 24 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned about 33 bases from the on-target adenosine of the target RNA. In some embodiments, the second internal loop can be positioned about 34 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop can be positioned about 7 bases from the on-target adenosine of the target RNA to about 30 bases from the on-target adenosine of the target RNA, and the second internal loop can be positioned about 18 bases from the on-target adenosine of the target RNA to about 34 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 5 bases from the on-target adenosine of the target RNA to about 15 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 12 bases from the on-target adenosine of the target RNA to about 40 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 6 bases from the on-target adenosine of the target RNA to about 20 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 15 bases from the on-target adenosine of the target RNA to about 38 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 5 bases from the on-target adenosine of the target RNA to about 20 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 18 bases from the on-target adenosine of the target RNA to about 38 bases from the on-target adenosine of the target RNA.In some embodiments, the first internal loop may be positioned about 5 bases from the on-target adenosine of the target RNA to about 15 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 18 bases from the on-target adenosine of the target RNA to about 38 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 1 base from the on-target adenosine of the target RNA to about 20 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 12 bases from the on-target adenosine of the target RNA to about 40 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 5 bases from the on-target adenosine of the target RNA to about 20 bases from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 12 bases from the on-target adenosine of the target RNA to about 40 bases from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 5 bases away from the on-target adenosine of the target RNA to about 20 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 15 bases away from the on-target adenosine of the target RNA to about 40 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 10 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 34 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 15 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 33 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 6 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 34 bases away from the on-target adenosine of the target RNA.In some embodiments, the first internal loop may be positioned about 12 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 34 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 6 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 33 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 12 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 24 bases away from the on-target adenosine of the target RNA. In some embodiments, the first internal loop may be positioned about 10 bases away from the on-target adenosine of the target RNA, and the second internal loop may be positioned about 33 bases away from the on-target adenosine of the target RNA. In some embodiments, the engineered guide RNA may include a cytosine present in the guide-target RNA scaffold opposite the on-target adenosine edited by the RNA editing entity when the engineered guide RNA is hybridized to the target RNA, thereby forming an A / C mismatch in the duplex RNA substrate. In some embodiments, the first internal loop and the second internal loop may be positioned the same number of bases from the A / C mismatch relative to the base of the first internal loop and the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned at least about one base away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned about one base away from the A / C mismatch to about 20 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned at least about five bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch.In some embodiments, the first internal loop can be positioned about 5 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 5 bases from the A / C mismatch to about 15 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned at least about 6 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 6 bases from the A / C mismatch to about 20 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned at least about 7 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is at the base of the first internal loop that is closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned about 7 bases from the A / C mismatch to about 30 bases from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop may be positioned at least about 12 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop may be positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop may be positioned at least about 15 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 15 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 15 bases from the A / C mismatch to about 38 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned at least about 18 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 18 bases from the A / C mismatch to about 38 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 18 bases from the A / C mismatch to about 35 bases from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 20 bases from the A / C mismatch to about 33 bases from the A / C mismatch, relative to the base of the second internal loop closest to the A / C mismatch.In some embodiments, the second internal loop can be positioned about 24 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned about 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 10 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop can be positioned about 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned about 15 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop may be positioned about 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned about 6 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop may be positioned about 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop may be positioned about 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop may be positioned about 34 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 6 bases away from the A / C mismatch relative to the base of the first internal loop that is closest to the A / C mismatch, and the second internal loop can be positioned about 33 bases away from the A / C mismatch relative to the base of the second internal loop that is closest to the A / C mismatch.In some embodiments, the first internal loop can be positioned about 12 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop can be positioned about 24 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the first internal loop can be positioned about 10 bases away from the A / C mismatch relative to the base of the first internal loop closest to the A / C mismatch, and the second internal loop can be positioned about 33 bases away from the A / C mismatch relative to the base of the second internal loop closest to the A / C mismatch.
[0033] In some embodiments, the target RNA can be ABCA4 RNA. In this example, an engineered guide RNA comprising a barbell macrofootprint sequence forms a guide-target RNA scaffold with the ABCA4 RNA upon hybridization with the ABCA4 mRNA. The ABCA4 guide-target RNA scaffold includes a right internal loop (e.g., right barbell) and a left internal loop (e.g., left barbell) emerging from the barbell macrofootprint sequence, if present.
[0034] In some embodiments, a guide RNA targeting ABCA4 may comprise a first internal loop and a second internal loop that are independently positioned as follows: the first internal loop is located about 2 or more bases upstream (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) of the on-target adenosine, and about 20 .... The first internal loop is located downstream (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2) or at a distance of about 2 bases to about 20 bases upstream (e.g., 3-19, 4-18, 5-17, 6-16, 7-15, 8-14, 9-13, 10-12) of the on-target adenosine, and the second internal loop is located at a distance of about 12 bases or more downstream (e.g., 14-13, 10-12) of the on-target adenosine. For example, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), approximately 40 bases or less downstream of the on-target adenosine (e.g., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2), or at a distance of about 12 bases to about 40 bases downstream of the on-target adenosine (e.g., 13-39, 14-38, 15-37, 16-36, 17-35, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27).
[0035] In some embodiments, the guide RNA targeting ABCA4 has a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 27 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 32 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 9 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine. a first internal loop positioned about 10 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 13 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 14 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; or a first internal loop positioned about 15 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine.
[0036] In some embodiments, an engineered guide RNA targeting ABCA4 may include a first internal loop located approximately 15 bases upstream of the target adenosine to be edited and a second internal loop located approximately 33 bases downstream of the target adenosine to be edited. The engineered guide RNA may exhibit excellent on-target editing and low off-target editing, resulting in less than about 3% off-target editing. Thus, an engineered guide RNA targeting ABCA4 and forming a barbell macrofootprint with the first internal loop at position -15 and the second internal loop at position +33 may be highly efficient and specific, with greater than about 40% on-target editing and less than about 3% off-target editing by ADARs.
[0037] In some embodiments, the target RNA may be GAPDH RNA. In this example, an engineered guide RNA comprising a barbell macrofootprint sequence forms a guide-target RNA scaffold with GAPDH RNA upon hybridization with GAPDH mRNA. The GAPDH guide-target RNA scaffold comprises a right internal loop (e.g., right barbell) and a left internal loop (e.g., left barbell) emerging from the barbell macrofootprint sequence, if present.
[0038] In some embodiments, a guide RNA targeting GAPDH may comprise a first internal loop and a second internal loop that are independently positioned as follows: the first internal loop is located about 2 or more bases upstream of the on-target adenosine (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20), and about 20 or more bases upstream of the on-target adenosine. The first internal loop is located downstream (e.g., 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2) or at a distance of about 2 bases to about 20 bases upstream (e.g., 3-19, 4-18, 5-17, 6-16, 7-15, 8-14, 9-13, 10-12) of the on-target adenosine, and the second internal loop is located at a distance of about 12 bases or more downstream (e.g., 14-13, 10-12) of the on-target adenosine. For example, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), approximately 40 bases or less downstream of the on-target adenosine (e.g., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21 , 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2), or at a distance of about 12 bases to about 40 bases downstream of the on-target adenosine (e.g., 13-39, 14-38, 15-37, 16-36, 17-35, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27).
[0039] In some embodiments, the guide RNA targeting GAPDH has a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 27 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 32 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 9 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine. a first internal loop positioned about 10 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 13 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 14 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; or a first internal loop positioned about 15 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine.
[0040] In some embodiments, the target RNA can be MAPT RNA. In this example, an engineered guide RNA comprising a barbell macrofootprint sequence forms a guide-target RNA scaffold with MAPT RNA upon hybridization with MAPT mRNA. The MAPT guide-target RNA scaffold comprises a right internal loop (e.g., right barbell) and a left internal loop (e.g., left barbell) emerging from the barbell macrofootprint sequence, if present.
[0041] In some embodiments, a guide RNA targeting MAPT may comprise a first internal loop and a second internal loop that are independently positioned as follows: the first internal loop is about 2 or more bases upstream of the on-target adenosine (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20), the second internal loop is about 20 or less bases upstream of the on-target adenosine (e.g., 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), the third internal loop is about 10 or more bases upstream of the on-target adenosine (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, 20), the fourth internal loop is about 10 or less ... The second internal loop is positioned at a distance of about 12 bases or more downstream of the on-target adenosine (e.g., 12, 13, 14, 15, 16, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2), or about 2 bases to about 20 bases upstream of the on-target adenosine (e.g., 3-19, 4-18, 5-17, 6-16, 7-15, 8-14, 9-13, 10-12), and the second internal loop is positioned at a distance of about 12 bases or more downstream of the on-target adenosine (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 9, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), approximately 40 bases or less downstream of the on-target adenosine (e.g., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2), or about 12 bases to about 40 bases downstream of the on-target adenosine (e.g., 13-39, 14-38, 15-37, 16-36, 17-35, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27), or at a distance of 24 bases, 26 bases, 28 bases, or 30 bases downstream of the on-target adenosine of the target RNA.
[0042] In some embodiments, the guide RNA targeting MAPT has a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 27 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 32 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 9 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine. The second internal loop may include: a first internal loop positioned about 10 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 13 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 14 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine; or a first internal loop positioned about 15 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine.
[0043] In some embodiments, the target RNA can be LRRK2 RNA. In this example, an engineered guide RNA comprising a barbell macrofootprint sequence forms a guide-target RNA scaffold with the LRRK2 RNA upon hybridization with the LRRK2 mRNA. The LRRK2 guide-target RNA scaffold, if present, comprises a right internal loop (e.g., right barbell) and a left internal loop (e.g., left barbell) emerging from the barbell macrofootprint sequence.
[0044] In some embodiments, a guide RNA targeting LRRK2 may comprise a first internal loop and a second internal loop that are independently positioned as follows: the first internal loop is about 2 or more bases upstream of the on-target adenosine (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20), the second internal loop is about 20 or less bases upstream of the on-target adenosine (e.g., 19, The second internal loop is positioned at a distance of about 12 or more bases downstream of the on-target adenosine (e.g., 12, 13, 14, 15, 16, 17, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2), or about 2 bases to about 20 bases upstream of the on-target adenosine (e.g., 3-19, 4-18, 5-17, 6-16, 7-15, 8-14, 9-13, 10-12), and the second internal loop is positioned at a distance of about 12 or more bases downstream of the on-target adenosine (e.g., 12, 13, 14, 15, 16, 17, 18). , 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), approximately 40 bases or less downstream of the on-target adenosine (e.g., 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 , 9, 8, 7, 6, 5, 4, 3, 2), about 12 bases to about 40 bases downstream of the on-target adenosine (e.g., 13-39, 14-38, 15-37, 16-36, 17-35, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27), or 24, 26, 28, or 30 bases downstream of the on-target adenosine of the target RNA.
[0045] In some embodiments, the guide RNA targeting LRRK2 has a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 27 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and a second internal loop positioned about 32 bases downstream of the on-target adenosine; a first internal loop positioned about 5 bases upstream of the on-target adenosine and an internal loop positioned about 33 bases downstream of the on-target adenosine; a first internal loop positioned about 9 bases upstream of the on-target adenosine and a second internal loop positioned about 33 bases downstream of the on-target adenosine. the first internal loop positioned about 10 bases upstream of the on-target adenosine and the second internal loop positioned about 33 bases downstream of the on-target adenosine; the first internal loop positioned about 13 bases upstream of the on-target adenosine and the second internal loop positioned about 33 bases downstream of the on-target adenosine; the first internal loop positioned about 14 bases upstream of the on-target adenosine and the second internal loop positioned about 33 bases downstream of the on-target adenosine; or the first internal loop positioned about 15 bases upstream of the on-target adenosine and the second internal loop positioned about 33 bases downstream of the on-target adenosine.
[0046] In some embodiments, an engineered guide RNA targeting LRRK2 may comprise a first internal loop positioned at a distance of about 10 bases upstream of the on-target adenosine and a second internal loop positioned at a distance of about 34 bases downstream of the on-target adenosine.
[0047] In some embodiments, the first barbell or the second barbell may be a symmetric internal loop comprising 8 bases. In some embodiments, either the first barbell or the second barbell may not comprise 8 bases.
[0048] In some embodiments, the first barbell or the second barbell may be a symmetric internal loop comprising six bases. In some embodiments, either the first barbell or the second barbell may not comprise six bases.
[0049] Microfootprint array As disclosed herein, engineered guide RNAs containing barbell macrofootprint sequences contain microfootprint sequences between the barbell macrofootprints that, upon hybridization to a target RNA, generate potential structures that manifest as one or more structural features.
[0050] In some embodiments, the present disclosure provides engineered guide RNAs that comprise a barbell macrofootprint. In some embodiments, the present disclosure provides engineered guide RNAs that comprise a microfootprint. In some embodiments, the present disclosure provides engineered guide RNAs that comprise a macrofootprint and a microfootprint, where the macrofootprint comprises a barbell (or internal loop) near the 5' and 3' ends of the guide-target RNA scaffold, and the microfootprint comprises other structural features, including, but not limited to, a mismatch, a symmetric internal loop, an asymmetric internal loop, a symmetric bulge, or an asymmetric bulge. For example, the engineered guide RNAs disclosed herein can have a macrofootprint and a microfootprint of an A / G mismatch at a local off-target adenosine. The engineered guide RNAs disclosed herein can have a macrofootprint and a microfootprint of a 1 / 0 asymmetric bulge (formed by deletion of an A in the target RNA and a U in the engineered guide RNA) at a local off-target adenosine. The engineered guide RNAs disclosed herein may have a barbell macrofootprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and a microfootprint of an A / G mismatch at a local off-target adenosine. The engineered guide RNAs disclosed herein may have a barbell macrofootprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and a microfootprint of a 1 / 0 asymmetric bulge (formed by the deletion of an A in the target RNA and a U in the engineered guide RNA) mismatch at a local off-target adenosine.In some embodiments, the engineered guide RNAs disclosed herein may comprise a barbell macrofootprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and microfootprints of a 5 / 5 symmetric loop, a 1 / 1 G / G mismatch, and a 3 / 3 symmetric bulge, while also reducing local off-target adenosine editing. In some embodiments, the barbell macrofootprint is designed to form an internal loop at position -14 and an internal loop at position +22 relative to the target adenosine (position 0). In some embodiments, the barbell macrofootprint is designed to form an internal loop at position -20 and an internal loop at position +26 relative to the target adenosine (position 0).
[0051] A microfootprint sequence of a guide RNA that includes a potential structure (e.g., a "potential structure guide RNA") may include a portion of the sequence that, upon hybridization to a target RNA, forms at least a portion of a structural feature other than a single A / C mismatch feature at the target adenosine to be edited. Thus, a structural feature of a potential guide RNA is potential in that the structural feature is formed, formed only, or substantially formed upon hybridization of the guide RNA to the target RNA. In some embodiments, the potential structural feature that is formed upon hybridization to the target RNA comprises at least two consecutive nucleotides of the guide RNA. In some instances, the potential structural feature may include a mismatch in addition to the A / C mismatch feature at the target adenosine to be edited, where this additional mismatch provides an increased amount of editing of the target RNA in the presence of an RNA editing entity compared to an otherwise identical guide RNA lacking the additional mismatch. In some embodiments, the engineered guide RNAs disclosed herein lack an RNA editing entity recruitment domain that is formed and present in the absence of binding to the target RNA. A guide-target RNA scaffold, as disclosed herein, can be the resulting double-stranded RNA duplex formed upon hybridization of a guide RNA to a target RNA, where the guide RNA prior to hybridization to the target RNA includes a portion of the sequence that forms at least a portion of the structural feature upon hybridization to the target RNA, other than a single A / C mismatch feature at the target adenosine to be edited. Thus, the guide-target RNA scaffold has the structural feature formed within the double-stranded RNA duplex. For example, the guide-target RNA scaffold can have two or more features selected from the group consisting of a bulge, a mismatch, an internal loop, a hairpin, a wobble base pair, and any combination thereof. In some embodiments, the engineered guide RNA with the potential structure is formed in the absence of binding to the target RNA and lacks a present RNA editing entity recruitment domain.In some embodiments, the engineered guide RNA with the potential structure further comprises a recruitment domain that is formed and present in the absence of binding to the target RNA.
[0052] In some examples, the engineered guide RNAs disclosed herein do not recruit RNA editing entities when present in aqueous solution and not bound to a target RNA molecule. In some examples, (i) the engineered guide RNAs do not contain any bulges, internal loops, or hairpins when present in aqueous solution and not bound to a target RNA molecule; (ii) the engineered guide RNAs do not contain any bulges, internal loops, or hairpins that recruit human ADAR1 with a dissociation constant of less than about 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, or 1,000 nM, as determined by in vitro assays, when present in aqueous solution and not bound to a target RNA molecule; (iii) the engineered guide RNAs are configured to adopt structural features (together with the target RNA) that recruit RNA editing entities when at least partially bound to a target RNA molecule, thereby forming a guide-target RNA scaffold; or (iv) any combination thereof. In some examples, when an engineered guide RNA is present in aqueous solution and not bound to a target RNA molecule, it binds to an RNA editing entity with a dissociation constant of approximately 100 nM, 200 nM, 300 nM, 400 nM, 500 nM, 600 nM, 700 nM, 800 nM, 900 nM, or 1,000 nM or more. In some examples, when an engineered guide RNA is present in aqueous solution and not bound to a target RNA molecule, it binds to an RNA editing entity with a dissociation constant of approximately 500 nM or more. In some examples, when an engineered guide RNA is present in aqueous solution and not bound to a target RNA molecule, it lacks the structural features described herein. In some examples, when an engineered guide RNA is present in aqueous solution and not bound to a target RNA molecule, it does not contain any bulges, internal loops, or hairpins. In some examples, the engineered guide RNAs disclosed herein may be linear and free of any structural features when in aqueous solution and not bound to a target RNA molecule.
[0053] In some examples, the engineered guide RNA can be configured to facilitate editing of nucleotides or polynucleotide bases in a region of a target RNA by a subject RNA editing entity. To facilitate editing, the engineered guide RNA of the present disclosure can recruit an RNA editing entity (e.g., adenosine deaminase).
[0054] If an engineered guide RNA does not contain an RNA editing entity recruitment domain that is formed and present in the absence of binding to a target RNA, the engineered guide RNA may still be able to associate with a subject RNA editing entity (e.g., an ADAR) to facilitate editing of the target RNA, regulate expression of a polypeptide encoded by the subject target RNA, or both. This may be achieved by the presence of structural features that emerge from the potential structure formed upon hybridization of the guide RNA and the target RNA. The structural features may include any one of a mismatch, a symmetric bulge, an asymmetric bulge, a symmetric internal loop, an asymmetric internal loop, a hairpin, a wobble base pair, a structured motif, a circularized RNA, a chemical modification, or any combination thereof. In some aspects, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of the engineered guide RNA of the present disclosure to the target RNA. The resulting dsRNA is also referred to herein as a "guide-target RNA scaffold." Features corresponding to one of several structural features that may be present in the guide-target RNA scaffolds of the present disclosure are described herein. Examples of features include a mismatch, a bulge (symmetric or asymmetric), an internal loop (symmetric or asymmetric internal loop), or a hairpin (a hairpin containing a non-targeting domain). An engineered guide RNA of the present disclosure may have 1 to 50 features.For example, the engineered guide RNAs of the present disclosure may be any of the following: 1-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 5-20, 5-25, 5-30, 5-35, 5-40, 5-45, 5-50, 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-11, 1-12, 1-13, 1-14, 1-15, 1-16, 1-17, 1-18, 1-19, 1-20 , 1-21, 1-22, 1-23, 1-24, 1-25, 1-26, 1-27, 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, 1-35, 1-36, 1-37, 1-38, 1-39, 1-40, 1-41, 1-42, 1-43, 1-44, 1-45, 1-46, 1-47, 1-48, 1-49, 4-5, 2-10, 20-40, 10-40, 20-50, 30-50, 4-7, or 8-10 features. In some examples, the engineered guide RNA comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, It may have 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 features.
[0055] As disclosed herein, a "structured motif" comprises two or more features in a dsRNA substrate (e.g., a guide-target RNA scaffold).
[0056] As described herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. As disclosed herein, a "mismatch" refers to a single nucleotide in a guide RNA that is not paired with an opposing single nucleotide in a target RNA within the guide-target RNA scaffold. A mismatch can include any two single nucleotides that do not base pair, are not complementary, or both. If the number of involved nucleotides on the guide RNA and target RNA sides exceeds one, the resulting structure is no longer considered a mismatch, but rather is considered a "bulge" or "internal loop" depending on the size of the structural feature. In some embodiments, the mismatch can be an A / C mismatch as described above (e.g., an A / C mismatch contained in a microfootprint sequence). An A / C mismatch can include a C in an engineered guide RNA of the present disclosure opposite an A in the target RNA. An A / C mismatch can include an A in an engineered guide RNA of the present disclosure opposite a C in the target RNA. In certain embodiments, the G / G mismatch can comprise a G in the engineered guide RNA of the present disclosure opposite a G in the target RNA. In some embodiments, a mismatch located 5' to the editing site can facilitate base flipping of the target A to be edited. The mismatch can also serve to confer sequence specificity. Thus, the mismatch can be a structural feature formed from a potential structure provided by the engineered potential guide RNA. In some embodiments, the mismatch comprises a G / G mismatch. In further embodiments, the mismatch comprises an A / C mismatch, where the A can be in the target RNA and the C can be in the targeting sequence of the engineered guide RNA. In other embodiments, the A in the A / C mismatch can be the base of a nucleotide in the target RNA edited by the subject RNA editing entity.
[0057] In some instances, the structural feature is present when the engineered guide RNA is associated with a target RNA. The structural feature of the engineered guide RNA may form a substantially linear two-dimensional structure. The structural feature of the engineered guide RNA may include a linear region, a stem-loop, a cruciform, a toehold, a mismatched bulge, or any combination thereof. In some instances, the structural feature may include a stem, a hairpin loop, a pseudoknot, a bulge, an internal loop, a multi-loop, a G-quadruplex, or any combination thereof. In some instances, the engineered guide RNA may adopt an A-form, a B-form, a Z-form, or any combination thereof. In some embodiments, the linear engineered guide RNA may include a ribozyme domain. In some embodiments, the linear engineered guide RNA may not include a ribozyme domain.
[0058] In some cases, the structural feature can be a hairpin. In some cases, the engineered guide RNA can lack a hairpin domain (e.g., the engineered guide RNA does not form an intramolecular hairpin in the absence of hybridization to the target RNA). In other cases, the engineered guide RNA can include one hairpin domain, or two or more hairpin domains. The hairpin can be located anywhere in the guide RNA. As disclosed herein, a "hairpin" includes an RNA duplex in which a portion of a single-stranded RNA folds back on itself to form an RNA duplex. A portion of the single-stranded RNA strand folds back on itself due to having nucleotide sequences that base-pair with each other, and the nucleotide sequences are separated by an intervening sequence that does not base-pair with itself, thus forming a base-paired portion and a non-base-paired, intervening loop portion. The hairpin can have an overall duplex structure length of 10 to 500 nucleotides. The loop portion of the hairpin can be 3 to 15 nucleotides in length. A hairpin can be present in any of the engineered guide RNAs disclosed herein. The engineered guide RNAs disclosed herein may have 1 to 10 hairpins. In some embodiments, the engineered guide RNAs disclosed herein have 1 hairpin. In some embodiments, the engineered guide RNAs disclosed herein have 2 hairpins. As disclosed herein, the hairpins may be recruiting hairpins or non-recruiting hairpins. The hairpins may be present anywhere within the engineered guide RNAs of the present disclosure. In some embodiments, one or more hairpins may be present at the 3' end of the engineered guide RNA of the present disclosure, at the 5' end of the engineered guide RNA of the present disclosure, or within the targeting sequence of the engineered guide RNA of the present disclosure, or any combination thereof.
[0059] As disclosed herein, a hairpin may refer to a recruitment hairpin, a non-recruitment hairpin, or any combination thereof. A "recruitment hairpin" refers to a hairpin that at least partially recruits or mobilizes an RNA editing entity (e.g., ADAR) as disclosed herein. In yet another aspect, the structural feature comprises a non-recruitment hairpin. As disclosed herein, a non-recruitment hairpin does not have the primary function of recruiting an RNA editing substance. In some examples, a non-recruitment hairpin does not recruit an RNA editing substance. A non-recruitment hairpin may exhibit functionality that improves the localization of an engineered guide RNA to a target RNA. In some embodiments, a non-recruitment hairpin exhibits functionality that improves the localization of an engineered guide RNA to a region of a target RNA for hybridization. In some embodiments, a non-recruitment hairpin improves intranuclear retention. In some embodiments, a non-recruitment hairpin comprises a hairpin derived from U7 snRNA. Thus, non-recruiting hairpins, such as hairpins derived from U7 snRNA, are preformed structural features that can be encoded for constructs containing engineered guide RNAs. Potential structural guide RNAs can have at least some elements of barbell macrofootprint and microfootprint sequences. Furthermore, preformed structures, such as U7 hairpins, smOPT sequences, or both, can be added to or bolted onto potential structural guide RNAs to form engineered guide RNAs. Engineered guide RNAs can be expressed, for example, from constructs containing a promoter (e.g., U1, U6, U7) and optionally operably linked to a terminator sequence (e.g., a U7 terminator sequence or a U7 truncated terminator sequence). The Sm-binding domain can include an RNA-binding domain that recognizes RNA sequences containing U-rich portions with high specificity. In some cases, the Sm-binding domain can be involved in both protein oligomerization and specific RNA binding.
[0060] Hairpins of the present disclosure can be of any length, hi some embodiments, hairpins can be from about 10 to 500 nucleotides or more. In some cases, the hairpin may be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 2, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 5, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 24 04, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262,263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 3, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 42 84, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, or more nucleotides. In other cases, hairpins are 10-20, 10-30,10~40, 10~50, 10~60, 10~70, 10~80, 10~90, 10~100, 10~110, 10~120, 10~130, 10~140, 10~150, 10~160, 10~170, 10~180, 10~190, 10~200, 10~210, 10~220, 10~230, 10~240, 10~250, 10~260, 10~270, 10~280, It may contain 10 to 290, 10 to 300, 10 to 310, 10 to 320, 10 to 330, 10 to 340, 10 to 350, 10 to 360, 10 to 370, 10 to 380, 10 to 390, 10 to 400, 10 to 410, 10 to 420, 10 to 430, 10 to 440, 10 to 450, 10 to 460, 10 to 470, 10 to 480, 10 to 490, or 10 to 500 nucleotides.
[0061] In another embodiment, the structural feature comprises a wobble base. A "wobble base pair" refers to two bases that weakly pair. For example, a wobble base pair in the present disclosure may refer to a G paired with a U. Thus, a wobble base pair may be a structural feature formed from a potential structure provided by an engineered potential guide RNA.
[0062] In some cases, the structural feature may be a bulge. As disclosed herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. As disclosed herein, a "bulge" refers to a structure that is formed substantially only upon formation of the guide-target RNA scaffold, in which consecutive nucleotides in either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposing strand. A bulge may alter the secondary or tertiary structure of the guide-target RNA scaffold. A bulge may have 0 to 4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold and 1 to 4 consecutive nucleotides on the target RNA side of the guide-target RNA scaffold, or a bulge may have 0 to 4 nucleotides on the target RNA side of the guide-target RNA scaffold and 1 to 4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold. However, as used herein, bulge does not refer to a structure in which a single nucleotide involved in an engineered guide RNA and a single nucleotide involved in a target RNA do not base-pair; a single nucleotide involved in an engineered guide RNA and a single nucleotide involved in a target RNA that do not base-pair is referred to herein as a "mismatch." Furthermore, if the number of involved nucleotides on either the guide RNA or the target RNA exceeds four, the resulting structure is no longer considered a bulge, but rather an internal loop. In some embodiments, a guide-target RNA scaffold of the present disclosure has two bulges. In some embodiments, a guide-target RNA scaffold of the present disclosure has three bulges. In some embodiments, a guide-target RNA scaffold of the present disclosure has four bulges. In some cases, bulges comprising consecutive nucleotides in either the engineered guide RNA or the target RNA that are not complementary to their positional counterparts on the opposite strand flank both sides of the hybridized complementary dsRNA region.Thus, a bulge can be a structural feature formed from a potential structure resulting from an engineered potential guide RNA. In some cases, a bulge comprising consecutive nucleotides in either the engineered guide RNA or the target RNA that are not complementary to their positional counterparts on the opposite strand flanks both sides of the hybridized complementary dsRNA region. The bulge can be located at any position in the guide RNA other than the last nucleotide at either the 5' or 3' end. In some cases, the bulge can be located about 30 to about 70 nucleotides from the 5' or 3' hydroxyl.
[0063] In some embodiments, the presence of a bulge in the guide-target RNA scaffold can position or help position ADARs to selectively edit target A in the target RNA and reduce off-target editing of non-target A(s) in the target RNA. In some embodiments, the presence of a bulge in the guide-target RNA scaffold can recruit or help recruit additional amounts of ADARs. The bulge in the guide-target RNA scaffold disclosed herein can recruit other proteins, such as other RNA editing substances. In some embodiments, the bulge located 5' of the editing site can facilitate base flipping of the target A to be edited. The bulge can also help to impart sequence specificity to the A of the target RNA to be edited compared to other A(s) present in the target RNA. For example, the bulge can help direct ADAR editing by constraining it to a direction that results in selective editing of target A.
[0064] In some embodiments, selective editing of target A is achieved by positioning target A between two bulges (e.g., between a 5'-end bulge and a 3'-end bulge based on an engineered guide RNA). In some embodiments, the two bulges are both symmetrical. In some embodiments, the two bulges are each formed by two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and two nucleotides on the target RNA side of the guide-target RNA scaffold. In some embodiments, the two bulges are each formed by three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. In some embodiments, the two bulges are each formed by four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. In some embodiments, target A is located between two bulges and is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 from the bulge (e.g., from the 5'-end bulge or the 3'-end bulge). , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 , 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 1 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158,159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189 9, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 2 20, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 , 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281 1, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342 , 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, or 400 nucleotides.The additional structural feature is located between the bulges (e.g., between the 5'-end bulge and the 3'-end bulge). In some embodiments, the mismatch in the bulge comprises a nucleotide base for editing in the target RNA (e.g., an A / C mismatch in the bulge, where a portion of the bulge in the engineered guide RNA comprises a mismatched C to an A in a portion of the bulge in the target RNA, and the A is edited).
[0065] In certain aspects, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) can be formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The bulge can be symmetric or asymmetric. A "symmetric bulge" is formed when there are equal numbers of nucleotides on each side of the bulge. A symmetric bulge can have 2 to 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold or on the target RNA side of the guide-target RNA scaffold. For example, a symmetric bulge of a guide-target RNA scaffold of the present disclosure can have equal numbers of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. A symmetric bulge of the present disclosure can be formed by two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and two nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric bulge of the present disclosure can be formed by three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetrical bulge of the present disclosure can be formed by four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, the symmetrical bulge can be a structural feature formed from a potential structure provided by the engineered potential guide RNA.
[0066] In some cases, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) may be formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The bulge may be a symmetric bulge or an asymmetric bulge. An "asymmetric bulge" is formed when there are different numbers of nucleotides on each side of the bulge. For example, an asymmetric bulge of a guide-target RNA scaffold of the present disclosure may have different numbers of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. An asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 1 nucleotide on the target RNA side of the guide-target RNA scaffold. An asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the target RNA side of the guide-target RNA scaffold and 1 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. An asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the engineered guide ...2 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotide on the target RNA side of the guide-target RNA scaffold and 2 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and 3 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotide on the target RNA side of the guide-target RNA scaffold and 3 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and 4 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotide on the target RNA side of the guide-target RNA scaffold and 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 1 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and 2 nucleotides on the target RNA side of the guide-target RNA scaffold.The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by two nucleotides on the target RNA side of the guide-target RNA scaffold and three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by two nucleotides on the target RNA side of the guide-target RNA scaffold and four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by three nucleotides on the target RNA side of the guide-target RNA scaffold and four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. Thus, the asymmetric bulge can be a structural feature formed from a potential structure resulting from an engineered potential guide RNA.
[0067] In some embodiments, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) can be formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. As disclosed herein, "internal loop" refers to a structure that is substantially formed only upon formation of the guide-target RNA scaffold, in which nucleotides in either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposite strand, and one side of the internal loop, either the target RNA side of the guide-target RNA scaffold or the engineered guide RNA side, has five or more nucleotides. If the number of nucleotides involved on both the guide RNA side and the target RNA side is reduced to less than five, the resulting structure is no longer considered an internal loop, but rather a bulge or mismatch, depending on the size of the structural feature. The internal loop can be a symmetric internal loop or an asymmetric internal loop. An internal loop present near the editing site can aid in base flipping of target A in the target RNA being edited.
[0068] In some embodiments, selective editing of target A is achieved by placing target A between two loops (e.g., between the 5' and 3' terminal loops based on the engineered guide RNA). In some embodiments, one side of the internal loop, on either the target RNA side or the engineered polynucleotide side of the guide target RNA scaffold, can be formed by 5 to 150 nucleotides. One side of the internal loop can be formed by 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 120, 135, 140, 145, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1000 nucleotides, or any number of nucleotides in between. One side of the internal loop can be formed by 5 nucleotides. One side of the internal loop can be formed by 10 nucleotides. One side of the internal loop may be formed by 15 nucleotides. One side of the internal loop may be formed by 20 nucleotides. One side of the internal loop may be formed by 25 nucleotides. One side of the internal loop may be formed by 30 nucleotides. One side of the internal loop may be formed by 35 nucleotides. One side of the internal loop may be formed by 40 nucleotides. One side of the internal loop may be formed by 45 nucleotides. One side of the internal loop may be formed by 50 nucleotides. One side of the internal loop may be formed by 55 nucleotides. One side of the internal loop may be formed by 60 nucleotides. One side of the internal loop may be formed by 65 nucleotides. One side of the internal loop may be formed by 70 nucleotides. One side of the internal loop may be formed by 75 nucleotides. One side of the internal loop may be formed by 80 nucleotides. One side of the internal loop may be formed by 85 nucleotides. One side of the internal loop may be formed by 90 nucleotides. One side of the internal loop may be formed by 95 nucleotides.One side of the internal loop may be formed by 100 nucleotides. One side of the internal loop may be formed by 110 nucleotides. One side of the internal loop may be formed by 120 nucleotides. One side of the internal loop may be formed by 130 nucleotides. One side of the internal loop may be formed by 140 nucleotides. One side of the internal loop may be formed by 150 nucleotides. One side of the internal loop may be formed by 200 nucleotides. One side of the internal loop may be formed by 250 nucleotides. One side of the internal loop may be formed by 300 nucleotides. One side of the internal loop may be formed by 350 nucleotides. One side of the internal loop may be formed by 400 nucleotides. One side of the internal loop may be formed by 450 nucleotides. One side of the internal loop may be formed by 500 nucleotides. One side of the internal loop may be formed by 600 nucleotides. One side of the internal loop can be formed by 700 nucleotides. One side of the internal loop can be formed by 800 nucleotides. One side of the internal loop can be formed by 900 nucleotides. One side of the internal loop can be formed by 1000 nucleotides. Thus, the internal loop can be a structural feature formed from a potential structure provided by an engineered potential guide RNA.
[0069] As described herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. A "symmetric internal loop" is formed when the same number of nucleotides are present on both sides of the internal loop. For example, a symmetric internal loop of a guide-target RNA scaffold of the present disclosure can have the same number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 5 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 8 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 9 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 10 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 15 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 15 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 20 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 20 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 30 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 30 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 40 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 40 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 50 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 60 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 60 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 70 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 70 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 80 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 80 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 90 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 90 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 100 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 110 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 110 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 120 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 120 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure can be formed by 130 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 130 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 140 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 140 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 150 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 200 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 250 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 250 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 300 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 350 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 350 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 400 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 450 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 450 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 500 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 600 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 600 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure can be formed by 700 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 700 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 800 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 800 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 900 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 900 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 1000 nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, a symmetric internal loop can be a structural feature formed from potential structures provided by potential engineered guide RNAs.
[0070] In some embodiments, target A is located between two loops and is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65 , 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 5, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136 , 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 1 99, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 23 0, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261,262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297 7, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, In some embodiments, the length of the loop is 8, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, or 400 nucleotides. In some embodiments, the additional structural feature is located between the loops (e.g., between the 5'-end loop and the 3'-end loop). In some embodiments, the mismatch in the loop comprises a nucleotide base for editing in the target RNA (e.g., an A / C mismatch in the loop comprises a C mismatched to an A in a portion of the loop in the target RNA, and A is edited).
[0071] As disclosed herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. An "asymmetric internal loop" is formed when a different number of nucleotides is present on both sides of the internal loop. For example, the asymmetric internal loop of a guide-target RNA scaffold of the present disclosure can have a different number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold.
[0072] The asymmetric internal loop of the present disclosure can be formed by 5 to 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5 to 150 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different compared to the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 to 1,000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5 to 1,000 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different compared to the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and a 10-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 7-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and an 8-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and an 9-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and an 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and an 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by an 8-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 9-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by an 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 9-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by an 8-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by an 8-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 9-nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 10-nucleotide internal loop on the target RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 9 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. Thus, the asymmetric internal loop can be a structural feature formed from a potential structure provided by a potential engineered guide RNA.
[0073] Structural features, including loops, can be of any size, 5 bases or more. In some cases, the loop is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130 , 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1000 nucleotides. In some cases, the loops total at least about 5-10, 5-15, 10-20, 15-25, 20-30, 5-30, 5-40, 5-50, 5-60, 5-70, 5-80, 5-90, 5-100, 5-110, 5-120, 5-130, 5-140, 5-150, 5-200, 5-250, 5-300, 5-350, 5-400, 5-450, 5-500, 5-600, 5-700, 5-800, 5-900, 5-1000, 20-50 , 20~60, 20~70, 20~80, 20~90, 20~100, 20~110, 20~120, 20~130, 20~140, 20~150, 30~40, 30~50, 30~60, 30~70, 30~80, 30~90, 30~100, 30~110, 30~120, 30~130, 30~140, 30~150, 30~200, 30~250, 30~300, 30~350, 30~400, 30~450, 30~500, 30~600,30~700、30~800、30~900、30~1000、40~50、40~60、40~70、40~80、40~90、40~100、40~110、40~120、40~130、40~140、40~150、40~200、40~250、40~300、40~350、40~400、40~450、40~500、40~600、40~700、40~800、40~900、40~1000、50~60、50~70、50~80、50~90、50~100、50~110、50~120、50~130、50~140、50~150、50~200、50~250、50~300、50~350、50~400、50~450、50~500、50~600、50~700、50~800、50~900、50~1000、60~70、60~80、60~90、60~100、60~110、60~120、60~130、60~140、60~150、60~200、60~250、60~300、60~350、60~400、60~450、60~500、60~600、60~700、60~800、60~900、60~1000、70~80、70~90、70~100、70~110、70~120、70~130、70~140、70~150、70~200、70~250、70~300、70~350、70~400、70~450、70~500、70~600、70~700、70~800、70~900、70~1000、80~90、80~100、80~110、80~120、80~130、80~140、80~150、80~200、80~250、80~300、80~350、80~400、80~450、80~500、80~600、80~700、80~800、80~900、80~1000、90~100、90~110、90~120、90~130、90~140、90~150、90~200、90~250、90~300、90~350、90~400、90~450、90~500、90~600、90~700、90~800、90~900、90~1000、100~110、100~120、100~130、100~140、100~150、100~200、100~250、100~300、100~350、100~400、100~450、100~500、100~600、100~700、100~800、100~900、100~1000、110~120、110~130、110~140、110~150、110~200、110~250、110~300、110~350、110~400、110~450、110~500、110~600、110~700、110~800、110~900、110~1000、120~130、120~140、120~150、120~200、120~250、120~300、120~350、120~400、120~450、120~500、120~600、120~700、120~800、120~900、120~1000、130~140、130~150、130~200、130~250、130~300、130~350、130~400、130~450、130~500、130~600、130~700、130~800、130~900、130~1000、140~150、140~200、140~250、140~300、140~350、140~400、140~450、140~500、140~600、140~700、140~800、140~900、140~1000、150~200、150~250、150~300、150~350、150~400、150~450、150~500、150~600、150~700、150~800、150~900、150~1000、200~250、200~300、200~350、200~400、200~450、200~500、200~600、200~700、200~800、200~900、200~1000、250~300、250~350、250~400、250~450、250~500、250~600、250~700、250~800、250~900、250~1000、300~350、300~400、300~450、300~500、300~600、300~700、300~800、300~900、300~1000、350~400、350~450、350~500、350~600、350~700、350~800、350~900、350~1000、400~450、400~500、400~600、400~700、400~800、400~900、400~1000、500~600、500~700、500~800、500~900、500~1000、600~700、Contains 600 to 800, 600 to 900, 600 to 1000, 700 to 800, 700 to 900, 700 to 1000, 800 to 900, 800 to 1000, or 900 to 1000 bases.
[0074] In some examples, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of the engineered guide of the present disclosure to the target RNA. In some examples, the guide-target RNA scaffold comprises structural features that mimic those of naturally occurring ADAR substrates. In some examples, the naturally occurring ADAR substrate can be a Drosophila ADAR substrate. In some examples, the naturally occurring Drosophila ADAR substrate can be as shown in Figures 3 and 4 and comprises two bulges. The specific nucleotide interactions that form the structural features of the Drosophila substrate are annotated on the sequence listed in Figure 4 and include (1) an A to C mismatch, (2) a 5'G to G mismatch, (3) two wobble base pairs, (4) a mismatch at position -7 and an asymmetric bulge at position +11 (2 / 1-target / guide), and (5) an asymmetric bulge at position +6 (1 / 0-target / guide). In some examples, the structural features of the guide-target RNA scaffold mimic the structural features of the Drosophila substrate, in that the double-stranded substrate contains one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) structural features that are also present in the Drosophila substrate. In some examples, one or more structural features in the guide-target RNA scaffold share at least 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% sequence homology, length with one or more (e.g., 1, 2, 3, 4, 5, 6, or 7) structural features, or both with the naturally occurring Drosophila substrate. In some examples, one or more structural features in the double-stranded substrate do not share sequence homology with one or more structural features of the Drosophila substrate, or share less than 50% sequence homology. In some examples, one or more features in the double-stranded substrate can be positioned the same or similarly (relative to each other) to the structural features of the natural ADAR substrate.
[0075] In some cases, structural feature can be structural motif.As disclosed herein, " structural motif " comprises two or more structural features in guide-target RNA scaffold.Structural motif can comprise any combination of structural features as described herein to generate the ideal substrate for ADAR editing at precise position(s).These structural motifs can be artificially engineered to maximize ADAR editing, or can be modeled to repeat known ADAR substrates, or both.
[0076] Targeted Domains The engineered guide RNAs disclosed herein, which contain at least some elements of barbell macrofootprint and microfootprint sequences, can be engineered in any manner suitable for RNA editing. In some examples, the microfootprint and macrofootprint sequences described herein can be included as part of a targeting sequence that allows the engineered guide RNA to hybridize to a region of a target RNA molecule. The targeting sequence can also be referred to as a "targeting domain" or "targeting region."
[0077] In some cases, the targeting sequence of the engineered...
Claims
1. An engineered guide RNA or a polynucleotide sequence encoding said engineered guide RNA, wherein upon hybridization of said engineered guide RNA to a sequence of a target RNA, said engineered guide RNA and said sequence of said target RNA form a guide-target RNA scaffold, said guide-target RNA scaffold comprising: a region comprising at least one structural feature selected from the group consisting of a bulge, a wobble base pair, an internal loop, a mismatch, a hairpin, and any combination thereof, wherein upon contacting the guide-target RNA scaffold with an RNA editing entity, the RNA editing entity edits an on-target adenosine in the target RNA within the guide-target RNA scaffold; b. the engineered guide RNA or the polynucleotide sequence encoding the engineered guide RNA comprising a first internal loop and a second internal loop adjacent to opposite ends of the region of the guide-target RNA scaffold of (i), wherein the first internal loop is 5' of the region comprising the at least one structural feature and the second internal loop is 3' of the region comprising the at least one structural feature, and wherein the first internal loop and the second internal loop facilitate an increased amount of editing of the on-target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop.
2. An engineered guide RNA or a polynucleotide sequence encoding said engineered guide RNA, wherein upon hybridization, the engineered guide RNA and target RNA sequences form a guide-target RNA scaffold, said guide-target RNA scaffold comprising: a. a microfootprint comprising at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a wobble base pair, a hairpin, and any combination thereof, wherein upon contacting the guide-target RNA scaffold with an RNA editing entity, the RNA editing entity edits an on-target adenosine in the target RNA within the guide-target RNA scaffold; b. the engineered guide RNA or the polynucleotide sequence encoding the engineered guide RNA comprising a barbell macrofootprint comprising a first internal loop that is 5' of the microfootprint and a second internal loop that is 3' of the microfootprint, wherein the barbell macrofootprint facilitates an increased amount of the editing of the on-target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the barbell macrofootprint.
3. 3. The engineered guide RNA of Claim 1 or 2, wherein the first internal loop and the second internal loop facilitate a reduced amount of off-target adenosine editing in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop.
4. 4. The engineered guide RNA of any one of claims 1-3, wherein the first internal loop is a symmetric internal loop and the second internal loop is a symmetric internal loop.
5. 5. The engineered guide RNA of claim 4, wherein the first internal loop and the second internal loop are symmetric internal loops that are independently 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loops, wherein a first number is the number of nucleotides contributed to the symmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and a second number is the number of nucleotides contributed to the symmetric internal loop from the target RNA side of the guide-target RNA scaffold.
6. 4. The engineered guide RNA of any one of claims 1-3, wherein the first internal loop is an asymmetric internal loop and the second internal loop is an asymmetric internal loop.
7. the first inner loop and the second inner loop are independently: 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6 , 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10 , 11 / 12, 11 / 13, 11 / 14, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 10 / 14, 11 / 14, 12 / 14, 13 / 14, 15 / 14, 16 / 14, 17 / 14, 18 / 14, 19 / 14, 20 / 14, 5 / 15, 6 / 15, 7 / 15, 8 / 15, 9 / 15, 10 / 15, 11 / 15, 12 / 15, 13 / 15, 14 / 15, 16 / 15, 1 / 15 7, 15 / 18, 15 / 19, 15 / 20, 16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8,17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 18, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 2 7. The engineered guide RNA of claim 6, wherein the asymmetric internal loop is a 0 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop, a first number is the number of nucleotides contributed to the asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and a second number is the number of nucleotides contributed to the asymmetric internal loop from the target RNA side of the guide-target RNA scaffold.
8. 4. The engineered guide RNA of any one of claims 1-3, wherein the first internal loop is a symmetric internal loop and the second internal loop is an asymmetric internal loop.
9. The first inner loop is a symmetric inner loop that is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric inner loop, and the second inner loop is a symmetric inner loop that is a 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 1 5, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 11, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 14, 1 1 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 6 / 13, 7 / 13, 8 / 13, 9 / 13, 10 / 13, 11 / 13, 12 / 13, 14 / 13, 15 / 13, 16 / 13, 17 / 13, 18 / 13, 19 / 13, 20 / 13, 5 / 14, 6 / 14, 7 / 14, 8 / 14, 9 / 14, 10 / 14, 11 / 14, 12 / 14, 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14, 15 / 16, 15 / 17, 15 / 18, 15 / 19, 15 / 20,16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11, 17 / 12, 17 / 13, 17 / 14, 17 / 15, 17 / 16, 17 / 1 8, 17 / 19, 17 / 20, 18 / 5, 18 / 6, 18 / 7, 18 / 8, 18 / 9, 18 / 10, 18 / 11, 18 / 12, 18 / 13, 18 / 14, 18 / 15, 18 / 16, 18 / 17, 18 / 19, 18 / 20, 19 / 5, 19 / 6, 19 / 7, 19 / 8, 19 / 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 9. The engineered guide RNA of claim 8, wherein the asymmetric internal loop is a symmetric internal loop that ...
10. 4. The engineered guide RNA of any one of claims 1-3, wherein the first internal loop is an asymmetric internal loop and the second internal loop is a symmetric internal loop.
11. The first inner loop is 5 / 6, 5 / 7, 5 / 8, 5 / 9, 5 / 10, 5 / 11, 5 / 12, 5 / 13, 5 / 14, 5 / 15, 5 / 16, 5 / 17, 5 / 18, 5 / 19, 5 / 20, 6 / 5, 6 / 7, 6 / 8, 6 / 9, 6 / 10, 6 / 11, 6 / 12, 6 / 13, 6 / 14, 6 / 15, 6 / 16, 6 / 17, 6 / 18, 6 / 19, 6 / 20, 7 / 5, 7 / 6, 7 / 8, 7 / 9, 7 / 10, 7 / 11, 7 / 12, 7 / 13, 7 / 14, 7 / 15, 7 / 16, 7 / 17, 7 / 18, 7 / 19, 7 / 20, 8 / 5, 8 / 6, 8 / 7, 8 / 9, 8 / 10, 8 / 1 1, 8 / 12, 8 / 13, 8 / 14, 8 / 15, 8 / 16, 8 / 17, 8 / 18, 8 / 19, 8 / 20, 9 / 5, 9 / 6, 9 / 7, 9 / 8, 9 / 10, 9 / 11, 9 / 12, 9 / 13, 9 / 14, 9 / 15, 9 / 16, 9 / 17, 9 / 18, 9 / 19, 9 / 20, 10 / 5, 10 / 6, 10 / 7, 10 / 8, 10 / 9, 10 / 11, 10 / 12, 10 / 13, 10 / 14, 10 / 15, 10 / 16, 10 / 17, 10 / 18, 10 / 19, 10 / 20, 11 / 5, 11 / 6, 11 / 7, 11 / 8, 11 / 9, 11 / 10, 11 / 12, 11 / 13, 11 / 1 4, 11 / 15, 11 / 16, 11 / 17, 11 / 18, 11 / 19, 11 / 20, 12 / 5, 12 / 6, 12 / 7, 12 / 8, 12 / 9, 12 / 10, 12 / 11, 12 / 13, 12 / 14, 12 / 15, 12 / 16, 12 / 17, 12 / 18, 12 / 19, 12 / 20, 13 / 5, 13 / 6, 13 / 7, 13 / 8, 13 / 9, 13 / 10, 13 / 11, 13 / 12, 13 / 14, 13 / 15, 13 / 16, 13 / 17, 13 / 18, 13 / 19, 13 / 20, 14 / 5, 14 / 6, 14 / 7, 14 / 8, 14 / 9, 14 / 10, 14 / 11, 14 / 12 , 14 / 13, 14 / 15, 14 / 16, 14 / 17, 14 / 18, 14 / 19, 14 / 20, 15 / 5, 15 / 6, 15 / 7, 15 / 8, 15 / 9, 15 / 10, 15 / 11, 15 / 12, 15 / 13, 15 / 14, 15 / 16, 15 / 17, 15 / 18, 15 / 19, 15 / 20, 16 / 5, 16 / 6, 16 / 7, 16 / 8, 16 / 9, 16 / 10, 16 / 11, 16 / 12, 16 / 13, 16 / 14, 16 / 15, 16 / 17, 16 / 18, 16 / 19, 16 / 20, 17 / 5, 17 / 6, 17 / 7, 17 / 8, 17 / 9, 17 / 10, 17 / 11,12 / 17, 13 / 17, 14 / 17, 15 / 17, 16 / 17, 18 / 17, 19 / 17, 20 / 17, 5 / 18, 6 / 18, 7 / 18, 8 / 18, 9 / 18, 10 / 18, 11 / 18, 12 / 18, 13 / 18, 14 / 18, 15 / 18, 16 / 18, 17 / 18, 19 / 18, 20 / 18, 5 / 19, 6 / 19, 7 / 19, 8 / 19, 9, 19 / 10, 19 / 11, 19 / 12, 19 / 13, 19 / 14, 19 / 15, 19 / 16, 19 / 17, 19 / 18, 19 / 20, 20 / 5, 20 / 6, 20 / 7, 20 / 8, 20 / 9, 20 / 10, 20 / 11, 20 / 12, 20 / 13, 20 / 14, 20 / 15, 20 / 16, 20 / 17, 20 / 18, or 20 / 19 asymmetric internal loop 11. The engineered guide RNA of claim 10, wherein the first number is an asymmetric internal loop that is a 5 / 5, 6 / 6, 7 / 7, 8 / 8, 9 / 9, 10 / 10, 11 / 11, 12 / 12, 13 / 13, 14 / 14, 15 / 15, 16 / 16, 17 / 17, 18 / 18, 19 / 19, or 20 / 20 symmetric internal loop, wherein a first number is the number of nucleotides contributed to the symmetric internal loop or the asymmetric internal loop from the engineered guide RNA side of the guide-target RNA scaffold and a second number is the number of nucleotides contributed to the symmetric internal loop or the asymmetric internal loop from the target RNA side of the guide-target RNA scaffold.
12. 12. The engineered guide RNA of any one of claims 1-11, wherein the first internal loop and the second internal loop comprise the same number of bases.
13. 12. The engineered guide RNA of any one of claims 1-11, wherein the first internal loop and the second internal loop comprise a different number of bases.
14. 12. The engineered guide RNA of any one of claims 1-11, wherein the first internal loop comprises a greater number of bases than the second internal loop.
15. 12. The engineered guide RNA of any one of claims 1-11, wherein the second internal loop comprises a greater number of bases than the first internal loop.
16. 12. The engineered guide RNA of any one of claims 1-11, wherein the first internal loop and the second internal loop independently comprise at least about 5 bases to at least about 20 bases of the engineered guide RNA and at least about 5 bases to at least about 20 bases of the target RNA.
17. 17. The engineered guide RNA of any one of claims 1 to 16, wherein the engineered guide RNA comprises a cytosine that is present in the guide-target RNA scaffold opposite the on-target adenosine that is edited by the RNA editing entity when the engineered guide RNA is hybridized to the target RNA, thereby forming an A / C mismatch within the guide-target RNA scaffold.
18. 18. The engineered guide RNA of Claim 17, wherein the first internal loop and the second internal loop are positioned the same number of bases from the A / C mismatch relative to a base of the first internal loop and a base of the second internal loop that are closest to the A / C mismatch.
19. 19. The engineered guide RNA of any one of Claims 17-18, wherein the first internal loop is positioned at least about 5 bases away from the A / C mismatch relative to the base of the first internal loop that is closest to the A / C mismatch.
20. 19. The engineered guide RNA of any one of Claims 17-18, wherein the first internal loop is positioned from about 1 base away from the A / C mismatch to about 30 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch, and optionally the first internal loop is positioned 6 bases, 10 bases, 12 bases, or 15 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
21. 19. The engineered guide RNA of any one of Claims 17-18, wherein the second internal loop is positioned at least about 12 bases away from the A / C mismatch relative to the base of the second internal loop that is closest to the A / C mismatch.
22. 19. The engineered guide RNA of any one of Claims 17-18, wherein the second internal loop is positioned about 12 bases from the A / C mismatch to about 40 bases from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch, and optionally the second internal loop is positioned 24, 30, 33, or 34 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
23. 23. The engineered guide RNA of any one of claims 1 to 22, wherein the target RNA is an mRNA selected from the group consisting of ABCA4, APP, CFTR, DMPK, DUX4, GAPDH, GBA, GRN, HEXA, LIPA, LRRK2, MAPT, PINK1, PMP22, SERPINA1, SNCA, or SOD1, a fragment of any one of these, and any combination thereof.
24. 24. The engineered guide RNA of Claim 23, wherein the target RNA is ABCA4, and the ABCA4 comprises a targeted mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof.
25. 25. The engineered guide RNA of Claim 24, wherein the first internal loop is positioned about 5 bases away from the A / C mismatch to about 15 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
26. 26. The engineered guide RNA of Claim 25, wherein the first internal loop is positioned 15 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
27. 27. The engineered guide RNA of any one of Claims 24-26, wherein the second internal loop is positioned about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
28. 28. The engineered guide RNA of Claim 27, wherein the second internal loop is positioned 33 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
29. 29. The engineered guide RNA of any one of claims 24-28, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 1-105, 2729-2761, or 2772-2843.
30. 24. The engineered guide RNA of Claim 23, wherein the target RNA is APP and a targeted mutation is introduced into the RNA of APP such that a polypeptide encoded by the RNA of APP after modification comprises a polypeptide mutation selected from the group consisting of K670E, K670R, K670G, M671V, A673V, A673T, D672G, E682G, H684R, K687R, K687E, K687G, I712X, T714X, and any combination thereof.
31. 31. The engineered guide RNA of Claim 30, wherein the first internal loop is positioned about 5 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
32. 32. The engineered guide RNA of Claim 31, wherein the first internal loop is positioned 10 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
33. 33. The engineered guide RNA of any one of Claims 30-32, wherein the second internal loop is positioned about 15 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
34. 34. The engineered guide RNA of Claim 33, wherein the second internal loop is positioned 33 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
35. 35. The engineered guide RNA of any one of claims 30-34, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 112-114.
36. 24. The engineered guide RNA of Claim 23, wherein the target RNA is SERPINA1, wherein the SERPINA encodes a polypeptide comprising an E342K mutation.
37. 37. The engineered guide RNA of Claim 36, wherein the first internal loop is positioned about 5 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
38. 38. The engineered guide RNA of Claim 37, wherein the first internal loop is positioned 12 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
39. 39. The engineered guide RNA of any one of Claims 36-38, wherein the second internal loop is positioned about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
40. 40. The engineered guide RNA of Claim 39, wherein the second internal loop is positioned 24 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
41. 41. The engineered guide RNA of any one of claims 36-40, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2762-2768 or 3083-3086.
42. The target RNA is LRRK2, and the LRRK2 is E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E , Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165P, I1192V, H1216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647T, Y1699C, R1728H, R1728L , L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I2012T, G2019S, I2020T, T2031S 24. The engineered guide RNA of claim 23, encoding a polypeptide having a polypeptide mutation selected from the group consisting of: N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, Q2490NfsX3, and any combination thereof.
43. 43. The engineered guide RNA of Claim 42, wherein the first internal loop is positioned about 7 bases away from the A / C mismatch to about 30 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
44. 44. The engineered guide RNA of Claim 43, wherein the first internal loop is positioned 10 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
45. 45. The engineered guide RNA of any one of Claims 42-44, wherein the second internal loop is positioned about 18 bases away from the A / C mismatch to about 34 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
46. 46. The engineered guide RNA of Claim 45, wherein the second internal loop is positioned 34 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
47. 47. The engineered guide RNA of any one of Claims 42-46, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 118-167, 2686-2728, 2769-2771, 2844-3078, or 3081-3082.
48. 24. The engineered guide RNA of Claim 23, wherein the target RNA is SNCA, and the SNCA comprises a targeted mutation for RNA editing selected from the group consisting of: AUG at position 265 of exon 2, ATG to GTG at translation initiation site (TIS) at codon 1 and codon 5.
49. 49. The engineered guide RNA of Claim 48, wherein the first internal loop is positioned about 6 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
50. 50. The engineered guide RNA of Claim 49, wherein the first internal loop is positioned 6 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
51. 51. The engineered guide RNA of any one of Claims 48-50, wherein the second internal loop is positioned about 15 bases away from the A / C mismatch to about 38 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
52. 52. The engineered guide RNA of Claim 51, wherein the second internal loop is positioned 34 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
53. 53. The engineered guide RNA of any one of claims 48-52, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 2480-2681.
54. 24. The engineered guide RNA of Claim 23, wherein the target RNA is MAPT, and the MAPT comprises a targeted mutation for RNA editing at the translation start site (TIS).
55. 55. The engineered guide RNA of Claim 54, wherein the first internal loop is positioned about 5 bases away from the A / C mismatch to about 15 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
56. 56. The engineered guide RNA of Claim 55, wherein the first internal loop is positioned 15 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
57. 57. The engineered guide RNA of any one of Claims 54-56, wherein the second internal loop is positioned about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
58. 58. The engineered guide RNA of Claim 57, wherein the second internal loop is positioned 33 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
59. 59. The engineered guide RNA of any one of Claims 54-58, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 115-117, 1519-2479, or 2682-2685.
60. 24. The engineered guide RNA of Claim 23, wherein the target RNA is DUX4.
61. 61. The engineered guide RNA of Claim 60, wherein the first internal loop is positioned about 1 base away from the A / C mismatch to about 20 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
62. 62. The engineered guide RNA of Claim 61, wherein the first internal loop is positioned 6 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
63. 63. The engineered guide RNA of any one of Claims 60-62, wherein the second internal loop is positioned about 15 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
64. 64. The engineered guide RNA of Claim 63, wherein the second internal loop is positioned 33 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
65. 65. The engineered guide RNA of any one of claims 60-64, wherein the engineered guide RNA comprises a polynucleotide sequence having at least 80%, 85%, 90%, 92%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 172-1518.
66. 24. The engineered guide RNA of Claim 23, wherein the target RNA is GRN.
67. 67. The engineered guide RNA of Claim 66, wherein the first internal loop is positioned about 5 bases away from the A / C mismatch to about 20 bases away from the A / C mismatch, relative to a base of the first internal loop that is closest to the A / C mismatch.
68. 68. The engineered guide RNA of Claim 67, wherein the first internal loop is positioned 12 bases away from the A / C mismatch relative to a base of the first internal loop that is closest to the A / C mismatch.
69. 69. The engineered guide RNA of any one of Claims 66-68, wherein the second internal loop is positioned about 18 bases away from the A / C mismatch to about 38 bases away from the A / C mismatch, relative to a base of the second internal loop that is closest to the A / C mismatch.
70. 70. The engineered guide RNA of Claim 69, wherein the second internal loop is positioned 34 bases away from the A / C mismatch relative to a base of the second internal loop that is closest to the A / C mismatch.
71. 71. The engineered guide RNA of any one of claims 1 to 70, wherein the engineered guide RNA comprises a length of at least about 60 bases.
72. 72. The engineered guide RNA of any one of claims 1-71, wherein the engineered guide RNA comprises a length of about 65 bases to about 150 bases.
73. 73. The engineered guide RNA of any one of Claims 1-72, wherein the at least one structural feature comprises a bulge.
74. 74. The engineered guide RNA of Claim 73, wherein the bulge comprises an asymmetric bulge.
75. 74. The engineered guide RNA of Claim 73, wherein the bulge comprises a symmetric bulge.
76. 76. The engineered guide RNA of any one of Claims 73-75, wherein the bulges independently comprise from about 1 base to about 4 bases of the engineered guide RNA and from about 0 bases to about 4 bases of the target RNA.
77. 77. The engineered guide RNA of any one of Claims 1-76, wherein the at least one structural feature comprises an internal loop.
78. 78. The engineered guide RNA of Claim 77, wherein the internal loop comprises an asymmetric internal loop.
79. 78. The engineered guide RNA of Claim 77, wherein said internal loop comprises a symmetric internal loop.
80. 80. The engineered guide RNA of any one of Claims 77-79, wherein the internal loop independently comprises from about 5 to about 10 bases of either the engineered guide RNA or the target RNA.
81. 81. The engineered guide RNA of any one of claims 1-80, wherein the at least one structural feature comprises a hairpin.
82. 82. The engineered guide RNA of Claim 81, wherein the hairpin comprises a length of about 3 bases to about 15 bases long.
83. 83. The engineered guide RNA of any one of claims 1 to 82, wherein the RNA editing entity is endogenous to a mammalian cell.
84. 84. The engineered guide RNA of any one of claims 1 to 83, wherein the RNA editing entity is an adenosine deaminase acting on RNA (ADAR) enzyme, a catalytically active fragment thereof, or a fusion polypeptide thereof.
85. 85. The engineered guide RNA of Claim 84, wherein the RNA editing entity is the ADAR enzyme.
86. 86. The engineered guide RNA of Claim 85, wherein the ADAR enzyme comprises human ADAR (hADAR).
87. 86. The engineered guide RNA of Claim 85, wherein the ADAR enzyme comprises ADAR1 or ADAR2.
88. 88. The engineered guide RNA of any one of claims 1 to 87, wherein the target RNA is an mRNA or a pre-mRNA.
89. 89. The engineered guide RNA of any one of claims 1 to 88, further comprising at least one chemical modification.
90. 90. The engineered guide RNA of Claim 89, wherein the at least one chemical modification comprises a 2'-O-methyl group on a ribose sugar of a nucleotide of the engineered guide RNA.
91. 90. The engineered guide RNA of Claim 89, wherein the at least one chemical modification comprises a phosphothioate modification of the backbone of the engineered guide RNA.
92. 92. The engineered guide RNA of any one of Claims 1-91, wherein the engineered guide comprises a total polynucleotide length of at least about 65 bases.
93. 93. The engineered guide RNA of any one of claims 1-92, wherein the engineered guide comprises a total polynucleotide length range of about 65 bases to about 100 bases.
94. 94. The engineered guide RNA of any one of claims 1 to 93, wherein the engineered guide RNA is a circular guide RNA.
95. A polynucleotide encoding an engineered guide RNA according to any one of claims 1 to 94.
96. A delivery vehicle comprising an engineered guide RNA according to any one of claims 1 to 94, or a polynucleotide according to claim 95.
97. 97. The delivery vehicle of claim 96, wherein the delivery vehicle is selected from the group consisting of a delivery vector, a liposome, a particle, and any combination thereof.
98. 98. The delivery vehicle of any one of claims 96 to 97, comprising the delivery vectors, wherein at least one delivery vector comprises a viral vector.
99. 99. The delivery vehicle of claim 98, wherein the viral vector comprises an adeno-associated viral (AAV) vector or a derivative thereof.
100. The AAV vector or its derivative may be AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV14, AAV15, AAV16, AAV. rh8, AAV. rh10, AAV. rh20, AAV. rh39, AAV. Rh74, AAV. RHM4-1, AAV. hu37, AAV. Anc80, AAV. Anc80L65, AAV. 7m8, AAV. PHP. B, AAV2.5, AAV2tYF, AAV3B, AAV.
100. The delivery vehicle of claim 99, wherein the adeno-associated virus is derived from an adeno-associated virus having a serotype selected from the group consisting of AAV.LK03, AAV.HSC1, AAV.HSC2, AAV.HSC3, AAV.HSC4, AAV.HSC5, AAV.HSC6, AAV.HSC7, AAV.HSC8, AAV.HSC9, AAV.HSC10, AAV.HSC11, AAV.HSC12, AAV.HSC13, AAV.HSC14, AAV.HSC15, AAV.HSC16, and AAVhu68.
101. The delivery vehicle of claim 99 or 100, wherein the AAV vector or derivative thereof is a recombinant AAV (rAAV) vector, a hybrid AAV vector, a chimeric AAV vector, a single-stranded AAV (ss-AAV), a self-complementary AAV (scAAV) vector, or any combination thereof.
102. 1. A pharmaceutical composition comprising: a. an engineered guide RNA according to any one of claims 1 to 94, a polynucleotide according to claim 95, or a delivery vehicle according to any one of claims 96 to 101; b. A pharma- ceutically acceptable excipient, diluent, or carrier.
103. 103. A method of treating a disease in a subject in need thereof, comprising administering to the subject an effective amount of an engineered guide RNA of any one of claims 1-94, a polynucleotide of claim 95, a delivery vehicle of any one of claims 96-101, or a pharmaceutical composition of claim 102, wherein said effective amount is sufficient to treat said disease in said subject.
104. 104. The method of claim 103, wherein said administering is intrathecal, intraocular, intravitreal, retinal, intravenous, intramuscular, intraventricular, intracerebral, intracerebellar, intraventricular, intraparenchymal, subcutaneous, or a combination thereof.
105. The method of claim 103 or 104, wherein the disease is macular degeneration.
106. The method according to any one of claims 103 to 105, wherein the disease is Stargardt's disease.
107. The method of any one of claims 103 to 104, wherein the disease comprises a neurological disease.
108. 108. The method of claim 107, wherein the neurological disease comprises Parkinson's disease, Alzheimer's disease, a tauopathy, or dementia.
109. The method of any one of claims 103 to 104, wherein the disease comprises a liver disease.
110. 110. The method of claim 109, wherein the liver disease comprises cirrhosis.
111. 110. The method of claim 109, wherein the liver disease comprises alpha-1 antitrypsin deficiency (AAT deficiency).
112. 107. The method of claim 106, wherein the target RNA is ABCA4.
113. 113. The method of claim 112, wherein said ABCA4 comprises a targeted mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof.
114. The method of any one of claims 103 to 113, wherein the subject has been diagnosed with the disease.
115. 1. A method of improving the editing efficiency of an engineered guide RNA configured to facilitate editing of an adenosine in a target RNA via an RNA editing entity, wherein upon hybridization, sequences of the engineered guide RNA and the target RNA form a guide-target RNA scaffold, the guide-target RNA scaffold comprising a region comprising at least one structural feature selected from the group consisting of a bulge, a wobble base pair, an internal loop, a mismatch, a hairpin, and any combination thereof, and wherein upon contacting the guide-target RNA scaffold with an RNA editing entity, the RNA editing entity edits an on-target adenosine in the target RNA within the guide-target RNA scaffold; The method comprises inserting a first sequence and a second sequence into the engineered guide RNA that form a first internal loop and a second internal loop, respectively, on opposite ends of a region of the guide-target RNA scaffold when the engineered guide RNA is hybridized to the target RNA, wherein the first internal loop and the second internal loop facilitate an increased amount of editing of the on-target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop, thereby improving the editing efficiency of the engineered guide RNA.
116. 10. The engineered guide RNA of any one of claims 1 to 94, the polynucleotide of claim 95, the delivery vehicle of any one of claims 96 to 101, or the pharmaceutical composition of claim 102 for use in the treatment of a disease.
117. 117. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to claim 116, wherein the agent is administered via an intrathecal, intraocular, intravitreal, retinal, intravenous, intramuscular, intraventricular, intracerebellar, intracerebroventricular, intraparenchymal, or subcutaneous route, or a combination thereof.
118. 118. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to claim 116 or 117, wherein the disease is macular degeneration.
119. 119. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to any one of claims 116 to 118, wherein the disease is Stargardt's disease.
120. 118. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to any one of claims 116 to 117, wherein the disease comprises a neurological disease.
121. 121. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to claim 120, wherein the neurological disease comprises Parkinson's disease, Alzheimer's disease, a tauopathy, or dementia.
122. 118. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to any one of claims 116 to 117, wherein the disease comprises a liver disease.
123. 123. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to Claim 122, wherein the liver disease comprises cirrhosis.
124. 123. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to Claim 122, wherein the liver disease comprises alpha-1 antitrypsin deficiency (AAT deficiency).
125. 120. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to Claim 119, wherein the target RNA is ABCA4.
126. 126. The engineered guide RNA, polynucleotide, delivery vehicle, or pharmaceutical composition for use according to Claim 125, wherein said ABCA4 comprises a targeted mutation for RNA editing selected from the group consisting of G6320A, G5714A, G5882A, and any combination thereof.
